<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1102256874
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2009
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CIFLOX 200MG-100ML I.V. INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CIPROFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bag
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        120.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Al Hikma Pharmaceutical Portugal Lda" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Al Hikma Pharmaceutical Portugal Lda
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Ciflox contains the active substance ciprofloxacin. Ciprofloxacin is an antibiotic belonging to the fluoroquinolone family. Ciprofloxacin works by killing bacteria that cause infections. It only works with specific strains of bacteria.</p><p><strong>Adults</strong></p><p>Ciflox<strong> </strong>is used in adults to treat the following bacterial infections:</p><ul><li>Respiratory tract infections</li><li>Long lasting or recurring ear or sinus infections</li><li>Urinary tract infections</li><li>Genital tract infections in men and women</li><li>Gastro-intestinal tract infections and intra-abdominal infections</li><li>Skin and soft tissue infections</li><li>Bone and joint infections</li><li>Anthrax inhalation exposure</li></ul><p>Ciflox<strong> </strong>may be used in the management of patients with low white blood cell counts (neutropenia) who have a fever that is suspected to be due to a bacterial infection.</p><p>If you have a severe infection or one that is caused by more than one type of bacterium, you may be given additional antibiotic treatment in addition to Ciflox.</p><p><strong>Children and adolescents</strong></p><p>Ciflox is used in children and adolescents, under specialist medical supervision, to treat the following bacterial infections:</p><ul><li>Lung and bronchial infections in children and adolescents suffering from cystic fibrosis</li><li>Complicated urinary tract infections, including infections that have reached the kidneys (pyelonephritis)</li><li>Anthrax inhalation exposure</li></ul><p>Ciflox<strong> </strong>may also be used to treat other specific severe infections in children and adolescents when your doctor considered this necessary</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Ciflox:</strong></p><ul><li>If you are allergic to the active substance, to other quinolone drugs or to any of the other ingredients of this medicine (listed in section 6).</li><li>If you are taking tizanidine (see section 2: Other medicines and Ciflox).</li></ul><p><strong>Warnings and precautions </strong></p><p><em>Before taking this medicine</em></p><p>You should not take fluoroquinolone/quinolone antibacterial medicines, including ciprofloxacin, if you have experienced any serious adverse reaction in the past when taking a quinolone or fluoroquinolone. In this situation, you should inform your doctor as soon as possible.</p><p><em>Talk to your doctor before you are given Ciflox</em></p><ul><li>If you have ever had kidney problems because your treatment may need to be adjusted.</li><li>If you suffer from epilepsy or other neurological conditions.</li><li>If you have a history of tendon problems during previous treatment with antibiotics such as Ciflox.</li><li>If you are diabetic because you may experience a risk of hypoglycaemia with ciprofloxacin.</li><li>If you have myasthenia gravis (a type of muscle weakness) because symptoms can be exacerbated.</li><li>If you have been diagnosed with an enlargement or &ldquo;bulge&rdquo; of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm).</li><li>If you have experienced a previous episode of aortic dissection (a tear in the aorta wall).</li><li>If you have been diagnosed with leaking heart valves (heart valve regurgitation).</li><li>If you have a family history of aortic aneurysm or aortic dissection or congenital heart valve disease, or other risk factors or predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, Turner syndrome, Sj&ouml;gren&rsquo;s syndrome [an inflammatory autoimmune disease], or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet&acute;s disease, high blood pressure, or known atherosclerosis, rheumatoid arthritis [a disease of the joints] or endocarditis [an infection of the heart]).</li><li>If you have heart problems. Caution should be taken when using ciprofloxacin, if you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), have salt imbalance in the blood (especially low level of potassium or magnesium in the blood), have a very slow heart rhythm (called &lsquo;bradycardia&rsquo;), have a weak heart (heart failure), have a history of heart attack (myocardial infarction), you are female or elderly or you are taking other medicines that result in abnormal ECG changes (see section 2: Other medicines and Ciflox).</li><li>If you or a member of your family is known to have a deficiency in glucose-6-phosphate dehydrogenase (G6PD), since you may experience a risk of anaemia with ciprofloxacin.</li></ul><p>For the treatment of some genital tract infections, your doctor can prescribe another antibiotic in addition to ciprofloxacin. If there is no improvement in symptoms after 3 days of treatment, please consult your doctor.</p><p><strong>While under treatment with Ciflox</strong></p><p>Tell your doctor immediately, if any of the following occurs during treatment with ciprofloxacin. Your doctor will decide whether treatment with ciprofloxacin needs to be stopped.</p><ul><li>Severe, sudden allergic reaction (an anaphylactic reaction/shock, angio-oedema). Even with the first dose, there is a rare chance that you may experience a severe allergic reaction with the following symptoms: tightness in the chest, feeling dizzy, feeling sick or faint, or experience dizziness on standing. If this happens, tell your doctor immediately since the administration of ciprofloxacin will have to be stopped.</li><li>Prolonged, disabling and potentially irreversible serious side effects. Fluoroquinolone/ quinolone antibacterial medicines, including ciprofloxacin, have been associated with very rare but serious side effects, some of them being long lasting (continuing months or years), disabling or potentially irreversible. This includes tendon, muscle and joint pain of the upper and lower limbs, difficulty in walking, abnormal sensations such as pins and needles, tingling, tickling, numbness or burning (paraesthesia), sensory disorders including impairment of vision, taste and smell, and hearing, depression, memory impairment, severe fatigue, and severe sleep disorders. If you experience any of these side effects after taking ciprofloxacin, contact your doctor immediately prior to continuing treatment. You and your doctor will decide on continuing the treatment considering also an antibiotic from another class.</li><li>Pain and swelling in the joints, and inflammation or rupture of tendons may occur rarely. Your risk is increased if you are elderly (above 60 years of age), have received an organ transplant, have kidney problems or if you are being treated with corticosteroids. Inflammation and ruptures of tendons may occur within the first 48 hours of treatment and even up to several months after stopping of ciprofloxacin therapy. At the first sign of pain or inflammation of a tendon (for example in your ankle, wrist, elbow, shoulder or knee), stop taking ciprofloxacin, contact your doctor and rest the painful area. Avoid any unnecessary exercise as this might increase the risk of a tendon rupture.</li><li>If you feel sudden, severe pain in your abdomen, chest or back, which can be symptoms of aortic aneurysm and dissection, go immediately to an emergency room. Your risk may be increased if you are being treated with systemic corticosteroids.</li><li>If you start experiencing a rapid onset of shortness of breath, especially when you lie down flat in your bed, or you notice swelling of your ankles, feet or abdomen, or a new onset of heart palpitations (sensation of rapid or irregular heartbeat), you should inform a doctor immediately.</li><li>If you suffer from epilepsy or other neurological conditions such as cerebral ischemia or stroke, you may experience side effects associated with the central nervous system. If seizure happens, stop taking ciprofloxacin and contact your doctor immediately.</li><li>You may rarely experience symptoms of nerve damage (neuropathy) such as pain, burning, tingling, numbness and/or weakness especially in the feet and legs or hands and arms. If this happens, stop taking ciprofloxacin and inform your doctor immediately in order to prevent the development of potentially irreversible condition.</li><li>You may experience psychiatric reactions after first administration of ciprofloxacin. If you suffer from depression or psychosis, your symptoms may become worse under treatment with ciprofloxacin. In rare cases, depression or psychosis can progress to thoughts of suicide, suicide attempts, or completed suicide. If this happens, contact your doctor immediately.</li><li>Quinolone antibiotics may cause an increase of your blood sugar levels above normal levels (hyperglycaemia), or lowering of your blood sugar levels below normal levels, potentially leading to loss of consciousness (hypoglycaemic coma) in severe cases (see section 4). This is important for people who have diabetes. If you suffer from diabetes, your blood sugar should be carefully monitored.</li><li>Diarrhoea may develop while you are on antibiotics, including ciprofloxacin, or even several weeks after you have stopped using them. If it becomes severe or persistent or you notice that your stool contains blood or mucus, stop taking ciprofloxacin and contact your doctor immediately, as this can be life-threatening. Do not take medicines that stop or slow down bowel movements.</li><li>If your eyesight becomes impaired or if your eyes seem to be otherwise affected, consult an eye specialist immediately.</li><li>Your skin becomes more sensitive to sunlight or ultraviolet (UV) light under treatment with ciprofloxacin. Avoid exposure to strong sunlight or artificial UV light such as sunbeds.</li><li>Tell the doctor or laboratory staff that you are taking Ciflox if you have to provide a blood or urine sample.</li><li>If you suffer from kidney problems, tell the doctor because your dose may need to be adjusted.</li><li>Ciprofloxacin may cause liver damage. If you notice any symptoms such as loss of appetite, jaundice (yellowing of the skin), dark urine, itching, or tenderness of the stomach, ciprofloxacin must be stopped immediately.</li><li>Ciprofloxacin may cause a reduction in the number of white blood cells and your resistance to infection may be decreased. If you experience an infection with symptoms such as fever and serious deterioration of your general condition, or fever with local infection symptoms such as sore throat/pharynx/mouth or urinary problems you should see your doctor immediately. A blood test will be taken to check possible reduction of white blood cells (agranulocytosis). It is important to inform your doctor about your medicine.</li></ul><p><strong>Other medicines and Ciflox</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Do not use ciprofloxacin together with tizanidine, because this may cause side effects such as low blood pressure and sleepiness (see section 2: You must not be given Ciflox).</p><p>The following medicines are known to interact with ciprofloxacin in your body. Using ciprofloxacin together with these medicines can influence the therapeutic effect of these medicines. It can also increase the probability of experiencing side effects.</p><p><em>Tell your doctor if you are taking:</em></p><ul><li>Vitamin K antagonists (e.g. warfarin, acenocoumarol, phenprocoumon or fluindione) or other oral anti-coagulants (to thin the blood).</li><li>Probenecid (for gout).</li><li>Methotrexate (for certain types of cancer, psoriasis, rheumatoid arthritis).</li><li>Theophylline (for breathing problems).</li><li>Tizanidine (for muscle spasticity in multiple sclerosis).</li><li>Olanzapine (an antipsychotic).</li><li>Clozapine (an antipsychotic).</li><li>Ropinirole (for Parkinson&rsquo;s disease).</li><li>Phenytoin (for epilepsy).</li><li>Cyclosporin (for skin conditions, rheumatoid arthritis and in organ transplantation).</li><li>Other medicines that can alter your heart rhythm: medicines that belong to the group of anti-arrhythmics (e.g. quinidine, hydroquinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide), tricyclic antidepressants, some antimicrobials (that belong to the group of macrolides), some antipsychotics.</li><li>Zolpidem (for sleep disorders).</li></ul><p><em>Ciprofloxacin may increase the levels of the following medicines in your blood:</em></p><ul><li>Pentoxifylline (for circulatory disorders).</li><li>Caffeine.</li><li>Duloxetine (for depression, diabetic nerve damage or incontinence).</li><li>Lidocaine (for heart conditions or anaesthetic use).</li><li>Sildenafil (e.g. for erectile dysfunction).</li><li>Agomelatine (for depression).</li></ul><p><strong>Ciflox with food and drink</strong></p><p>Food and drink does not affect your treatment with Ciflox.</p><p><strong>Pregnancy and breast-feeding </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>It is preferable to avoid the use of Ciflox during pregnancy.</p><p>Do not take ciprofloxacin during breast-feeding because ciprofloxacin is excreted in breast milk and can be harmful for your child.</p><p><strong>Driving and using machines </strong></p><p>Ciprofloxacin may make you feel less alert. Some neurological adverse events can occur. Therefore, make sure you know how you react to Ciflox before driving a vehicle or operating machinery. If in doubt, talk to your doctor.</p><p><strong>Ciflox</strong><strong> </strong><strong>contains sodium</strong></p><p>Ciflox contains sodium. Each 200 ml of Ciflox 400 mg/200 ml Solution for Infusion contains 30.8 mmol (708.4 mg) sodium (main component of cooking/table salt). This is equivalent to 35.42% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>Talk to your doctor or pharmacist if you need 400 mg or more mgs daily for a prolonged period, especially if you have been advised to follow a low salt (sodium) diet</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will explain to you exactly how much Ciflox<strong> </strong>you will be given as well as how often and for how long. This will depend on the type of infection you have and how bad it is.</p><p>Tell your doctor if you suffer from kidney problems because your dose may need to be adjusted.</p><p>Treatment usually lasts between 5 and 21 days, but may be longer for severe infections.</p><p>Your doctor will give you each dose by slow infusion through a vein into your bloodstream. For children, the infusion duration is 60 minutes. In adult patients, infusion time is 60 minutes for 400 mg ciprofloxacin. Administering the infusion slowly helps prevent immediate side effects occurring.</p><p>Remember to drink plenty of fluids while you are taking this medicine.</p><p><strong>If you stop using </strong><strong>Ciflox</strong></p><p>If you stop your course of Ciflox, it is important that you finish the course of treatment even if you begin to feel better after a few days. If you stop using this medicine too soon your infection may not be completely cured and the symptoms of the infection may return or get worse. You might also develop resistance to the antibiotic.</p><p>If you have any further questions about the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong><em>The following section contains the most serious side effects that you can recognise yourself:</em></strong></p><p>Stop taking ciprofloxacin and contact your doctor immediately in order to consider another antibiotic treatment if you notice any of the following serious side effects:</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Seizure (see section 2: Warnings and precautions).</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><ul><li>Severe, sudden allergic reaction with symptoms such as tightness in the chest, feeling dizzy, sick or faint, or experience dizziness when standing up (anaphylactic shock) (see section 2: Warnings and precautions).</li><li>Tendon rupture, particularly affecting the large tendon at the back of the ankle (Achilles tendon) (see section 2: Warnings and precautions).</li></ul><p><strong>Very rare (may affect up to 1 in 10,000 people)</strong></p><ul><li>Severe, sudden allergic reaction with symptoms such as tightness in the chest, feeling dizzy, sick or faint, or experience dizziness when standing up (anaphylactic reaction) (see section 2: Warnings and precautions).</li><li>Muscle weakness, inflammation of the tendons which could lead to rupture of the tendon, particularly affecting the large tendon at the back of the ankle (Achilles tendon) (see section 2: Warnings and precautions).</li><li>A serious life-threatening skin rash, usually in the form of blisters or ulcers in the mouth, throat, nose, eyes and other mucous membranes such as genitals which may progress to widespread blistering or peeling of the skin (Stevens-Johnson syndrome, toxic epidermal necrolysis).</li></ul><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><ul><li>Unusual feelings of pain, burning tingling, numbness or muscle weakness in the extremities (neuropathy) (see section 2: Warnings and precautions).</li><li>A drug reaction that causes rash, fever, inflammation of internal organs, hematologic abnormalities and systemic illness (DRESS Drug Reaction with Eosinophilia and Systemic Symptoms, AGEP Acute Generalised Exanthematous Pustulosis).</li></ul><p><strong><em>Other side effects which have been observed during treatment with ciprofloxacin are listed below by how likely they are:</em></strong></p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>Nausea, diarrhoea, vomiting.</li><li>Joint pain and joint inflammation in children.</li><li>Local reaction at the injection site, rash.</li><li>Temporary increased amounts of substances in the blood (transaminases).</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Joint pain in adults.</li><li>Fungal superinfections.</li><li>A high concentration of eosinophils, a type of white blood cell, increased or decreased amounts of a blood clotting factor (thrombocytes).</li><li>Decreased appetite.</li><li>Hyperactivity, agitation, confusion, disorientation, hallucinations.</li><li>Headache, dizziness, sleeping problems, taste disorders, pins and needles, unusual sensitivity to stimuli of the senses, giddiness.</li><li>Eyesight problems including double vision.</li><li>Loss of hearing.</li><li>Rapid heartbeat (tachycardia).</li><li>Expansion of the blood vessels (vasodilation), low blood pressure.</li><li>Abdominal pain, digestive problems such as stomach upset (indigestion/heartburn), wind.</li><li>Liver disorders, increased amounts of one substance in the blood (bilirubin), jaundice (cholestatic icterus).</li><li>Itching, hives.</li><li>Poor kidney function, kidney failure.</li><li>Pains in your muscles and bones, feeling unwell (asthenia), fever, fluid retention.</li><li>Increase in blood alkaline phosphatase (a certain substance in the blood).</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><ul><li>Muscle pain, inflammation of the joints, increased muscle tone and cramping.</li><li>Inflammation of the bowel (colitis) linked to antibiotic use (can be fatal in very rare cases) (see section 2: Warnings and precautions).</li><li>Changes to the blood count (leukopenia, leukocytosis, neutropenia, anaemia), a drop in the number of red and white blood cells and platelets (pancytopenia), which may be fatal, bone-marrow depression which may also be fatal.</li><li>Allergic reaction, allergic swelling (oedema), rapid swelling of the skin and mucous membranes (angiooedema) (see section 2: Warnings and precautions).</li><li>Increased blood sugar (hyperglycaemia).</li><li>Decreased blood sugar (hypoglycaemia) (see section 2: Warnings and precautions).</li><li>Anxiety reaction, strange dreams, depression (potentially leading to thoughts of suicide, suicide attempts, or completed suicide), mental disturbances (psychotic reactions potentially leading to thoughts of suicide, suicide attempts, or completed suicide) (see section 2: Warnings and precuations).</li><li>Decreased skin sensitivity, tremor, migraine, disorder of sense of smell (olfactory disorders).</li><li>Tinnitus, impaired hearing.</li><li>Fainting, inflammation of the blood vessel (vasculitis).</li><li>Shortness of breath including asthmatic symptoms.</li><li>Pancreatitis.</li><li>Hepatitis, death of liver cells (liver necrosis) very rarely leading to life-threatening liver failure (see section 2: Warnings and precautions).</li><li>Sensitivity to light (see section 2: Warnings and precautions), small, pin-point bleeding under the skin (petechiae).</li><li>Blood or crystals in the urine, urinary tract inflammation.</li><li>Excessive sweating.</li><li>Increased levels of the enzyme amylase.</li></ul><p><strong>Very rare (may affect up to 1 in 10,000 people)</strong></p><ul><li>A special type of reduced red blood cell count (haemolytic anaemia); a dangerous drop in a type of white blood cells (agranulocytosis) (see section 2: Warnings and precautions).</li><li>Allergic reaction called serum sickness-like reaction (see section 2: Warnings and precautions).</li><li>Disturbed coordination, unsteady walk (gait disturbance), pressure on the brain (intracranial pressure and pseudotumor cerebri).</li><li>Visual colour distortions.</li><li>Various skin eruptions or rashes.</li><li>Worsening of the symptoms of myasthenia gravis (see section 2: Warnings and precautions).</li><li>Fatigue.</li><li>Memory impairment.</li></ul><p><strong>Not known (frequency cannot be estimated from the available data)</strong></p><ul><li>Syndrome associated with impaired water excretion and low levels of sodium (SIADH).</li><li>Feeling highly excited (mania) or feeling great optimism and overactivity (hypomania).</li><li>Abnormal fast heart rhythm, life-threatening irregular heart rhythm, alteration of the heart rhythm (called &lsquo;prolongation of QT interval&rsquo;, seen on ECG, electrical activity of the heart).</li><li>Influence on blood clotting (in patients treated with Vitamin K antagonists).</li><li>Loss of consciousness due to severe decrease in blood sugar levels (hypoglycaemic coma). See section 2: Warnings and precautions.</li></ul><p>Very rare cases of long lasting (up to months or years) or permanent adverse drug reactions, such as tendon inflammations, tendon rupture, joint pain, pain in the limbs, difficulty in walking, abnormal sensations such as pins and needles, tingling, tickling, burning, numbness or pain (neuropathy), depression, fatigue, sleep disorders, memory impairment, as well as impairment of hearing, vision, and taste and smell have been associated with administration of quinolone and fluoroquinolone antibiotics, in some cases irrespective of pre-existing risk factors.</p><p>Cases of an enlargement and weakening of the aortic wall or a tear in the aortic wall (aneurysms and dissections), which may rupture and may be fatal, and of leaking heart valves have been reported in patients receiving fluoroquinolones. See also section 2: Warnings and precautions.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store below 25&deg;C. Avoid refrigerating or freezing.</p><p>Store in the original package in order to protect from light and evaporation.</p><p>For single use only. Use immediately after first opening.</p><p>Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature (25&deg;C).</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is ciprofloxacin.</p><p>Each 200 ml of Ciflox 400 mg/200 ml Solution for Infusion contains 400 mg ciprofloxacin.</p><p>The other ingredients are lactic acid, sodium chloride, hydrochloric acid and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Ciflox 400 mg/200 ml Solution for Infusion is a clear colorless to slightly yellow solution in 250 ml polypropylene bags assembled with twist‐off.

Pack size: 1 Bag (200 ml).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder </strong></p><p>Jazeera Pharmaceutical Industries<br />Al-Kharj Road<br />P.O. Box 106229<br />Riyadh 11666, Saudi Arabia<br />Tel: + (966-11) 8107023, + (966-11) 2142472<br />Fax: + (966-11) 2078170<br />e-mail: SAPV@hikma.com<u> </u></p><p><strong>Manufacturer</strong></p><p>Hikma Farmaceutica (Portugal), S.A.</p><p>Estrada do Rio Da M&oacute;,</p><p>n.&deg;8, 8A e 8B, Ferven&ccedil;a</p><p>2705-906 Terrugem</p><p>Sintra, Portugal</p><p>Tel: + (351-2) 19608410</p><p>Fax: + (351-2) 19615102</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 10/2023; version number SA2.0.


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي سيفلوكس على المادة الفعالة سيبروفلوكساسين. سيبروفلوكساسين هو مضاد حيوي ينتمي إلى مجموعة الفلوروكينولونات. يعمل سيبروفلوكساسين على قتل البكتيريا التي تسبب العدوى. يعمل فقط مع سلالات محددة من البكتيريا.</p><p dir="RTL"><strong>البالغون</strong></p><p dir="RTL">يستخدم سيفلوكس في البالغين لعلاج العدوى البكتيرية التالية:</p><ul dir="rtl"><li>عدوى الجهاز التنفسي</li><li>عدوى الأذن أوالجيوب الأنفية طويلة الأمد أو المتكررة</li><li>عدوى المسالك البولية</li><li>عدوى الجهاز التناسلي عند الرجال والنساء</li><li>عدوى الجهاز الهضمي والعدوى داخل البطن</li><li>عدوى الجلد والأنسجة الملساء</li><li>عدوى العظام والمفاصل</li><li>التعرض لاستنشاق الجمرة الخبيثة</li></ul><p dir="RTL">يمكن استخدام سيفلوكس في علاج المرضى الذين يعانون من انخفاض عدد خلايا الدم البيضاء (قلة العدلات) والذين يعانون من حمى يشتبه في أنها ناجمة عن عدوى بكتيرية.</p><p dir="RTL">إذا كان لديك عدوى شديدة أو عدوى ناجمة عن أكثر من نوع واحد من البكتيريا، فقد يتم إعطاؤك مضاداً حيوياً آخر بالإضافة إلى سيفلوكس.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يستخدم سيفلوكس لدى الأطفال والمراهقين، تحت إشراف طبي متخصص، لعلاج العدوى البكتيرية التالية:</p><ul dir="rtl"><li>عدوى الرئة والقصبة الهوائية لدى الأطفال والمراهقين المصابين بالتليف الكيسي</li><li>عدوى المسالك البولية المعقدة، بما في ذلك العدوى التي وصلت إلى الكلى (التهاب الحويضة والكلية)</li><li>التعرض لاستنشاق الجمرة الخبيثة</li></ul><p dir="RTL">يمكن أيضاً استخدام سيفلوكس لعلاج حالات اخرى من العدوى الشديدة المحددة في الأطفال والمراهقين عندما يرى طبيبك ذلك ضرورياً.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب ألا تُعطى سيفلوكس:</strong></p><ul dir="rtl"><li>إذا كنت تعاني من حساسية للمادة الفعالة، لأي من أدوية الكينولونات الأخرى أو لأي من المواد الأخرى المستخدمة في تركيبة هذا الدواء (المذكورة في القسم 6).</li><li>إذا كنت تتناول تيزانيدين (انظر القسم 2: الأدوية الأخرى وسيفلوكس).</li></ul><p dir="RTL"><strong>الاحتياطات والتحذيرات &nbsp;</strong></p><p dir="RTL"><em>قبل استخدام هذا الدواء </em></p><p dir="RTL">يجب أن لا تستخدم الأدوية المضادة للبكتيريا الفلوروكينولون/كينولون، من ضمنها سيبروفلوكساسين، إذا عانيت في السابق من أي رد فعل عكسي خطير عندما تستخدم كينولون أو الفلوروكينولون. في هذه الحالة، يجب عليك إبلاغ طبيبك في أسرع وقت ممكن. &nbsp;</p><p dir="RTL"><em>تحدث مع طبيبك قبل إعطائك سيفلوكس:</em></p><ul dir="rtl"><li>إذا كنت قد عانيت في أي وقت مضى من مشاكل في الكلى لأن علاجك قد يحتاج إلى تعديل.</li><li>إذا كنت تعاني من الصرع أو غيره من الحالات التي تؤثر على الجهاز العصبي.</li><li>إذا كان لديك تاريخ مرضي من مشاكل في الأوتار أثناء علاجك السابق بمضادات حيوية مشابهة لسيفلوكس.</li><li>إذا كنت تعاني من مرض السكري لأنك قد تتعرض لخطر نقص سكر الدم مع استخدام سيبروفلوكساسين.</li><li>إذا كنت مصاباً بمرض الوهن العضلي الوبيل (نوع من أنواع ضعف العضلات) لأن أعراض المرض قد تتفاقم.</li><li>إذا تم تشخيصك بتضخم أو &quot;انتفاخ&quot; فى وعاء دموي عريض (أُمُّ الدَّمِ الأَبْهَرِيَّة أو أم الدم الوعاء المحيطي الكبير).</li><li>إذا تعرضت في السابق لنوبة تَسَلُّخُ أَبْهَر (تمزق في جدار الأبهر).</li><li>إذا تم تشخيصك بتسرب صمامات القلب (قلس صمامات القلب).</li><li>إذا كان لديك تاريخ مرضي من أُمُّ الدَّمِ الأَبْهَرِيَّة أو تَسَلُّخُ الأَبْهَر أو مرض خلقي في الصمامات القلبية أو عوامل خطر أخرى أو حالات مهيئة للمرض (مثل أمراض النسيج الضام على سبيل المثال متلازمة مارفان، أو متلازمة إيلرس دانلوس، متلازمة تيرنر، داء شوجرين ]مرض مناعي ذاتي التهابي[، أو الأمراض الوعائية مثل الْتِهابُ شَّرايينِ تكاياسو، الْتِهابُ الشِّرْيانِ ذو الخَلاَيا العِمْلاَقَة، داءُ بَهْجَتْ، ضغط الدم المرتفع، أو تصلب عصيدي معروف، التهاب المفاصل الروماتويدي ]مرض في المفاصل[ أو التهاب الشغاف ]عدوى في القلب[).</li><li>إذا كنت تعاني من مشاكل في القلب. ينبغي الحذر عند استخدام سيبروفلوكساسين إذا كنت قد وُلدت ولديك تاريخ مرضي عائلي لطول فترة QT (تظهر على التخطيط الكهربائي للقلب، وهو تسجيل للنشاط الكهربائي للقلب)، تعاني من عدم توازن الأملاح في الدم (وخاصة انخفاض مستوى البوتاسيوم أو المغنيسيوم في الدم)، تعاني من بطء شديد في نظم القلب (يُسمى &rsquo;بطء نظم القلب&lsquo;)، تعاني من ضعف بالقلب (فشل القلب)، لديك تاريخ مرضي من التعرض لنوبة قلبية (احتشاء عضلة القلب)، إذا كنت أنثى أو من كبار السن أو كنت تتناول أدوية أخرى تؤدي إلى تغيرات غير طبيعية في تخطيط القلب الكهربائي (انظر القسم 2: الأدوية الأخرى وسيفلوكس).</li><li>إذا كنت أنت أو أي من أفراد عائلتك مصاباً بنقص إنزيم نازعة هيدروجين الجلوكوز-6- فوسفات، لأنك قد تتعرض لخطر فقر الدم عند استخدامك سيبروفلوكساسين.</li></ul><p dir="RTL">لعلاج بعض حالات عدوى مجرى الجهاز التناسلي، قد يصف لك طبيبك مضاداً حيوياً آخراً بالإضافة إلى سيبروفلوكساسين. في حالة عدم تحسن الأعراض في غضون 3 أيام من العلاج، يُرجى استشارة طبيبك.</p><p dir="RTL"><strong>أثناء العلاج باستخدام سيفلوكس</strong></p><p dir="RTL">أخبر طبيبك فوراً، إذا حدث أي مما يلي أثناء العلاج باستخدام سيبروفلوكساسين. سيقرر طبيبك ما إذا كان الأمر يستدعي إيقاف العلاج بسيبروفلوكساسين.</p><ul dir="rtl"><li>رد فعل تحسسي شديد، مفاجئ (رد فعل/صدمة تأقية، وذمة وعائية). حتى مع أول جرعة، هناك فرصة نادرة بأن تُصاب برد فعل تحسسي شديد تصحبه الأعراض التالية: ضيق بالصدر، الشعور بالدوخة، الغثيان أو الإغماء، أو الشعور بدوخة عند الوقوف. إذا حدث هذا، فأخبر طبيبك فورًا لأنه سيتعين إيقاف إعطائك سيبروفلوكساسين. &nbsp;</li><li>آثار جانبية خطيرة، طويلة الأمد، معيقة ومن المحتمل أن تكون غير قابلة للعكس. تم ارتباط الأدوية المضادة للبكتيريا الفلوروكينولون/كينولون، من ضمنها سيبروفلوكساسين، مع آثار جانبية نادرة جداً لكنها خطيرة، بعضها يدوم طويلاً (تستمر لأشهر أو سنوات)، معيقة أو من المحتمل أن تكون غير قابلة للعكس. هذه تشمل ألم الأوتار، العضلات والمفاصل للأطراف العلوية والسفلية، صعوبة في المشي، أحاسيس غير طبيعية مثل الإبر والدبابيس، نخز، دغدغة، تنميل أو حرقة (مذل)، اضطرابات حسية تشمل خلل في الرؤية، التذوق والشم، والسمع، اكتئاب، خلل في الذاكرة، تعب شديد، واضطرابات شديدة في النوم. إذا عانيت من أي هذه الآثار الجانبية بعد أخذ سيبروفلوكساسين، تواصل مع طبيبك فوراً قبل الاستمرار في العلاج. أنت وطبيبك سوف تقرران الاستمرار في العلاج مع الأخذ بالاعتبار مضاد حيوي من فئة أخرى.</li><li>ألم وتورم في المفاصل، وقد يحدث بشكل نادر التهاب أو تمزق في الأوتار. يزداد الخطر إذا كنت من كبار السن (فوق عمر 60 عاماً)، تلقيت عملية زرع عضو، لديك مشاكل في الكلى أو إذا كنت تُعالج بالستيرويدات القشرية. قد تصاب بالتهاب وتمزقات الأوتار ما بين أول 48 ساعة من العلاج باستخدام سيبروفلوكساسين وحتى عدة شهور بعد التوقف عن استخدامه. عند ظهور أول علامة لألم أو التهاب للوتر (مثل في الكاحل، الرسغ، المرفق، الكتف أو الركبة)، توقف عن تناول سيبروفلوكساسين، تواصل مع طبيبك وأرِح موضع الألم. تجنب أي تمارين لا ضرورة لها لأن هذا قد يزيد من خطر تعرضك لتمزق في الأوتار.</li><li>إذا شعرت بألم شديد، مفاجئ في البطن، الصدر أو الظهر، والتي قد تكون علامات أُمُّ الدَّمِ الأَبْهَرِيَّة وتسلخ الأبهر، اذهب فوراً إلى الطوارئ. قد يزداد الخطر إذا كنت تتعالج بالستيرويدات القشرية الجهازية.</li><li>إذا بدأت تتعرض لضيق تنفس متسارع البدء، خاصةً عندما تستلقي متسطحاً على سريرك، أو تلاحظ تورم الكاحلين، القدم أو البطن، أو بداية جديدة لخفقان القلب (شعور بنبض قلب متسارع أو غير منتظم)، يجب عليك إخبار طبيب فوراً.</li><li>إذا كنت تعاني من الصرع أو أي حالة مرضية أخرى في الجهاز العصبي مثل نقص التروية في الدماغ أو السكتة الدماغية، فقد تعاني من آثار جانبية مرتبطة بالجهاز العصبي المركزي. في حالة تعرضك لنوبة تشنجية، توقف عن استخدام سيبروفلوكساسين وتواصل مع طبيبك فوراً. &nbsp;</li><li>قد تتعرض بشكل نادر لأعراض تلف الأعصاب (اعتلال عصبي) مثل الألم، الحرقة، النخز، التنميل و/أو الضعف خاصة في القدمين والأرجل أو اليدين والذراعين. في حالة حدوث ذلك، توقف عن استخدام سيبروفلوكساسين وأبلغ طبيبك فوراً من أجل منع تطور احتمالية حدوث حالة غير قابلة للعكس. &nbsp;</li><li>قد تتعرض لردود فعل نفسية حتى عند إعطائك سيبروفلوكساسين لأول مرة. إذا كنت تعاني من الاكتئاب أو الذُهان، قد تتفاقم أعراض المرض أثناء العلاج بسيبروفلوكساسين. في حالات نادرة، قد يتطور الاكتئاب أو الذُهان إلى التفكير في الانتحار محاولات الانتحار أو الانتحار فعلاً. إذا حدث هذا، تواصل مع طبيبك فوراً.</li><li>قد تسبب مجموعة المضادات الحيوية الكينولونات زيادة في مستويات سكر الدم فوق المستويات الطبيعية (ارتفاع سكر الدم)، أو انخفاض مستويات السكر في الدم إلى أقل من المستويات الطبيعية، من المحتمل أن تؤدي لفقدان الوعي (غيبوبة نقص سكر الدم) في الحالات الشديدة (انظر القسم 4). هذا مهم للأشخاص الذين يعانون من السكري. إذا كنت تعاني من السكري، يجب مراقبة سكر الدم لديك بعناية.</li><li>قد تُصاب بالإسهال أثناء استخدام المضادات الحيوية، بما فيها سيفلوكس، أو حتى بعد التوقف عن استخدامها بعدة أسابيع. إذا أصبح الإسهال شديداً أو مستمراً أو إذا لاحظت وجود دم أو مخاط بالبراز، فتوقف عن استخدام سيفلوكس وتواصل مع طبيبك فوراً، لأن هذا قد يشكل خطرًا على حياتك. لا تتناول أدوية لإيقاف أو إبطاء حركة الأمعاء.</li><li>إذا شعرت بقصور في الإبصار أو إذا بدا لك تأثر عينيك بشكل مختلف، فاستشر طبيب عيون متخصص فورًا.</li><li>يصبح الجلد أكثر حساسية لضوء الشمس أو لضوء الأشعة فوق البنفسجية أثناء العلاج بسيبروفلوكساسين. تجنب التعرض لضوء الشمس القوي أو أضواء الأشعة فوق البنفسجية الصناعية مثل أسرّة التسمير.</li><li>أخبر الطبيب أو العاملين في المختبر بأنك تستخدم سيفلوكس إذا كنت ستقدم عينة دم أو بول.</li><li>إذا كنت تعاني من مشاكل في الكلى، فأخبر الطبيب لأنه قد يحتاج إلى تعديل الجرعة.</li><li>قد يسبب سيبروفلوكساسين ضرر في الكبد. إذا لاحظت أي أعراض مثل فقدان الشهية، اليرقان (اصفرار في الجلد)، البول الداكن، الحكة، أو إيلام بالمعدة، يجب التوقف عن استخدام سيبروفلوكساسين فوراً.</li><li>قد يسبب سيبروفلوكساسين انخفاضًا في عدد خلايا الدم البيضاء وقد تنخفض مقاومتك للعدوى. إذا تعرضت لعدوى بأعراض مثل الحمى وتدهور خطير في الحالة العامة، أو الحمى المصحوبة بأعراض عدوى موضعية مثل عدوى الحلق/البلعوم/الفم أو مشاكل في المسالك البولية فيجب زيارة طبيبك فوراً. سيتم إجراء فحص للدم للتحقق من الانخفاض المحتمل لخلايا الدم البيضاء (ندرة المحببات). من المهم إبلاغ طبيبك عن دوائك.</li></ul><p dir="RTL"><strong>الأدوية الأخرى وسيفلوكس</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أية أدوية أخرى.</p><p dir="RTL">لا تستخدم سيبروفلوكساسين مع تيزانيدين، لأن هذا قد يؤدي إلى آثار جانبية، مثل انخفاض ضغط الدم والنعاس (انظر القسم 2: يجب ألا تُعطى سيفلوكس).</p><p dir="RTL">الأدوية التالية معروفة بتفاعلها مع سيبروفلوكساسين في الجسم. من الممكن أن يؤثر استخدام سيبروفلوكساسين مع هذه الأدوية على أثرها العلاجي. كما يمكن أن يزيد من احتمال التعرض لآثار جانبية.</p><p dir="RTL"><em>أبلغ طبيبك إذا كنت تتناول ما يلي:</em></p><ul dir="rtl"><li>مضادات فيتامين ك (مثل وارفارين، أسِينُوكُومارُول، فينبروكومون أو فلوينديون) أو غير ذلك من مضادات التخثر الفموية (لترقيق الدم).</li><li>بروبينيسيد (للنقرس).</li><li>ميثوتريكسات (لبعض أنواع السرطان، الصدفية، والتهاب المفاصل الروماتويدي).</li><li>ثيوفيللين (لمشاكل التنفس).</li><li>تيزانيدين (لفرط التوتر التشنجي للعضلات في مرض التصلب اللويحي المتعدد).</li><li>أولانزابين (مضاد للذهان).</li><li>كلوزابين (مضاد للذهان).</li><li>روبينيرول (لمرض الباركنسون).</li><li>&nbsp;فينيتوين (للصرع).</li><li>سيكلوسبورين (لحالات الجلد، التهاب المفاصل الروماتويدي وفي حالات زرع الأعضاء).</li><li>الأدوية الأخرى التي يمكن أن تغير نظم القلب: الأدوية التي تنتمي لمجموعة مضادات اضطراب نظم القلب (مثل كينيدين، هيدروكيندين، ديسوبيراميد، أميودارون، سوتالول، دوفيتيليد، إيبوتيليد)، مضادات الاكتئاب ثلاثية الحلقات، بعض مضادات الميكروبات (من الأدوية التي تنتمي إلى مجموعة الماكروليدات)، بعض مضادات الذهان.</li><li>زولبيديم (لاضطرابات النوم).</li></ul><p dir="RTL"><em>قد يزيد سيبروفلوكساسين من مستويات الأدوية التالية في الدم:</em></p><ul dir="rtl"><li>بينتوكسيفيلين (لاضطرابات الدورة الدموية).</li><li>كافيين.</li><li>دولوكسيتين (لعلاج الاكتئاب، تلف الأعصاب الناتج عن مرض السكري أو السلس).</li><li>ليدوكايين (لأمراض القلب أو لأغراض التخدير).</li><li>سيلدينافيل (مثل لعلاج ضعف الانتصاب).</li><li>أجوميلاتين (للاكتئاب).</li></ul><p dir="RTL"><strong>سيفلوكس مع الطعام والشراب</strong></p><p dir="RTL">لا يؤثر الطعام والشراب على علاجك باستخدام سيفلوكس.</p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">استشيري طبيبك أو الصيدلي قبل استخدام هذا الدواء إذا كنت حاملاً أو مرضعاً، تعتقدين بأنك حامل أو تخططين لذلك.</p><p dir="RTL">يُفضل تجنب استخدام سيفلوكس أثناء الحمل.</p><p dir="RTL">لا تستخدمي سيبروفلوكساسين أثناء الإرضاع لأن سيبروفلوكساسين يُفرز في حليب الثدي وقد يضر بطفلك.</p><p dir="RTL"><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قد يقلل سيبروفلوكساسين من انتباهك. يمكن أن تحدث بعض الآثار الجانبية للجهاز العصبي. لهذا، عليك أن تعرف أولاً مدى تأثرك بسيفلوكس قبل أن تقوم بالقيادة أو استخدام الآلات. إذا راودك أي شك، فتحدث مع طبيبك.</p><p dir="RTL"><strong>يحتوي سيفلوكس على الصوديوم</strong></p><p dir="RTL">يحتوي سيفلوكس على الصوديوم. يحتوي كل 200 مللتر من سيفلوكس 400 ملغم/200 مللتر محلول للتسريب على 30,8 ملمول (708,4 ملغم) صوديوم (المكون الرئيسي للطبخ/ملح الطعام). هذا يكافئ 35,42% من الكمية الغذائية اليومية القصوى الموصى بتناولها من الصوديوم للبالغين.</p><p dir="RTL">تحدث إلى طبيبك أو الممرض إذا كنت بحاجة إلى 400 ملغم أو ملغرامات أكثر يومياً لمدة طويلة، خاصة إذا كان قد تم نصحك باتباع نظام غذائي منخفض الملح (الصوديوم)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يشرح لك طبيبك بالضبط مقدار دواء سيفلوكس الذي سيتم إعطاؤه لك وكذلك عدد المرات والمدة. سيعتمد هذا على نوع العدوى لديك ومدى خطورتها.</p><p dir="RTL">أخبر طبيبك إذا كنت تعاني من مشاكل في الكلى لأن جرعتك قد تحتاج إلى تعديل.</p><p dir="RTL">يستمر العلاج عادة ما بين 5 إلى 21 يوماً، ولكن قد يكون أطول في حالات العدوى الشديدة.</p><p dir="RTL">سيعطيك طبيبك كل جرعة عن طريق التسريب البطيء عبر الوريد في مجرى دمك. للأطفال، مدة التسريب 60 دقيقة. في المرضى البالغين، مدة التسريب هي 60 دقيقة لـ 400 ملغم سيبروفلوكساسين. إن إعطاء التسريب ببطء يساعد على منع حدوث آثار جانبية فورية.</p><p dir="RTL">تذكر أن تشرب الكثير من السوائل أثناء استخدام هذا الدواء.</p><p dir="RTL"><strong>إذا توقفت عن استخدام سيفلوكس</strong></p><p dir="RTL">إذا توقفت عن استخدام<strong> </strong>سيفلوكس، فمن المهم أن تنهي دورة العلاج حتى إذا بدأت تشعر بالتحسن بعد بضعة أيام. إذا توقفت عن استخدام هذا الدواء في وقت مبكر جداً، فقد لا يتم علاج العدوى تماماً وقد تعود أعراض العدوى أو تزداد سوءاً. قد تصبح لديك أيضاً مقاومة للمضاد الحيوي.</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p dir="RTL"><strong><em>يوضح القسم التالي أخطر الآثار الجانبية التي يمكنك أن تتعرف عليها بنفسك:</em></strong></p><p dir="RTL">توقف عن تناول سيبروفلوكساسين وتواصل مع طبيبك فوراً للنظر في العلاج بمضاد حيوي آخر إذا لاحظت أي من الآثار الجانبية الخطيرة التالية:</p><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص)</strong></p><ul dir="rtl"><li>نوبات تشنجية (انظر القسم 2: الاحتياطات والتحذيرات).</li></ul><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص)</strong></p><ul dir="rtl"><li>رد فعل تحسسي شديد، مفاجئ يشمل أعراضًا مثل ضيق في الصدر، الشعور بدوخة، غثيان أو إغماء، أو الشعور بدوخة عند الوقوف (صدمة تأقية) (انظر القسم 2: الاحتياطات والتحذيرات).</li><li>تمزق في الأوتار، تحديداً الوتر الكبير في خلف الكاحل (وتر العرقوب) (انظر القسم 2: الاحتياطات والتحذيرات).</li></ul><p dir="RTL"><strong>نادرة جدًا</strong> <strong>(قد تؤثر على ما يصل إلى شخص واحد من كل 10000&nbsp;شخص)</strong></p><ul dir="rtl"><li>رد فعل تحسسي شديد، مفاجئ يشمل أعراضًا مثل ضيق في الصدر، الشعور بدوخة، غثيان أو إغماء، أو الشعور بدوخة عند الوقوف (رد فعل تأقي) (انظر القسم 2: الاحتياطات والتحذيرات).</li><li>ضعف في العضلات، التهاب في الأوتار قد يؤدي إلى تمزقها، تحديداً الوتر الكبير في خلف الكاحل (وتر العرقوب) (انظر القسم 2: الاحتياطات والتحذيرات).</li><li>طفح جلدي خطير يهدد الحياة، يظهر عادةً على شكل نفطات أو تقرحات في الفم، الحلق، الأنف، العينين وغير ذلك من الأنسجة المخاطية مثل أنسجة الأعضاء التناسلية الذي قد يتطور إلى انتشار كبير للنفطات أو تقشر للجلد (متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي).<strong>&nbsp;</strong></li></ul><p dir="RTL"><strong>غير معروفة</strong> <strong>(لا يمكن تقدير </strong><strong>تكرارها</strong><strong> </strong><strong>من البيانات المتوفرة)</strong></p><ul dir="rtl"><li>شعور غير معتاد بالألم، النخز الحارق، التنميل أو ضعف في عضلات الأطراف (اعتلال عصبي) (انظر القسم 2: الاحتياطات والتحذيرات).</li><li>رد فعل تجاه الدواء يسبب طفحاً، حمى، التهاب في الأعضاء الداخلية، اضطرابات في القيم الدموية وأمراض جهازية (رد فعل دوائي مصحوب بكثرة اليوزينيات وأعراض جهازية وداء البُثار الطفحي المعمم الحاد).</li></ul><p dir="RTL"><strong><em>الآثار الجانبية الأخرى المدرجة أدناه التي لوحظت أثناء العلاج باستخدام سيبروفلوكساسين مصنفّةً حسب مدى احتمال حدوثها:</em></strong></p><p dir="RTL"><strong>شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 10 </strong><strong>أ</strong><strong>شخاص)</strong></p><ul dir="rtl"><li>غثيان، إسهال، قيء.</li><li>ألم والتهاب في المفاصل لدى الأطفال.</li><li>رد فعل موضعي في مكان الحقن، طفح.</li><li>زيادة مؤقتة في تركيز بعض المواد في الدم (ناقلات الأمين).</li></ul><p dir="RTL"><strong>غير شائعة (قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص)</strong></p><ul dir="rtl"><li>ألم المفاصل عند البالغين.</li><li>حالات عدوى فطرية ثانوية.</li><li>زيادة تركيز يوزينات الدم، نوع من خلايا الدم البيضاء، زيادة أو نقص كميات أحد عوامل تجلط الدم (الصفيحات الدموية).</li><li>انخفاض الشهية.</li><li>فرط النشاط، الهياج، الارتباك، التوهان، الهلوسات.</li><li>الصداع، الدوخة، مشاكل في النوم، اضطرابات التذوق، الشعور بوخز كالإبر والدبابيس، حساسية غير معتادة لمثيرات الحواس، دُوام.</li><li>مشاكل في الإبصار تشمل ازدواجية الرؤية.</li><li>فقدان السمع.</li><li>سرعة نبضات القلب (تَسَارعُ القلب).</li><li>تمدد الأوعية الدموية (توسع الأوعية)، انخفاض ضغط الدم.</li><li>ألم البطن، مشاكل في الجهاز الهضمي مثل اضطراب المعدة (عسر الهضم/حرقة الفؤاد)، غازات.</li><li>اضطرابات الكبد، زيادة كميات مادة معينة في الدم (بِيليروبين)، يرقان (يرقان ركودي).</li><li>حكة، شرى.</li><li>ضعف وظائف الكلى، الفشل الكلوي.</li><li>ألم في العضلات والعظام، شعور بالاعتلال (الوهن)، حمى، احتباس السوائل.</li><li>زيادة في مستوى تركيز الفوسفاتاز القلوي في الدم (إحدى المواد التي توجد بالدم).</li></ul><p dir="RTL"><strong>نادرة (قد تؤثر على ما يصل إلى شخص واحد من كل 1000 شخص)</strong></p><ul dir="rtl"><li>ألم في العضلات، التهاب في المفاصل، زيادة توتر العضلات وتقلصها.</li><li>التهاب في الأمعاء (التهاب القولون) مرتبط باستخدام المضادات الحيوية (قد يصبح قاتلاً في حالات نادرة) (انظر القسم 2: الاحتياطات والتحذيرات).</li><li>تغير في عدد كريات الدم (قلة كريات الدم البيضاء، كثرة كريات الدم البيضاء، قلة العدلات، فقر الدم)، انخفاض في عدد كريات الدم الحمراء والبيضاء والصفيحات (قلة كريات الدم الشاملة) والذي قد يكون مميتاً، انخفاض نخاع العظم والذي قد يكون مميتاً أيضاً.</li><li>رد فعل تحسسي، تورم تحسسي (وذمة)، تورم سريع في الجلد والأنسجة المخاطية (الوذمة الوعائية) (انظر القسم 2: الاحتياطات والتحذيرات).</li><li>ارتفاع مستوى السكر في الدم (فرط سكر الدم).</li><li>انخفاض مستوى السكر في الدم (نقص سكر الدم) (انظر القسم 2: الاحتياطات والتحذيرات).</li><li>القلق، أحلام غريبة، اكتئاب (قد يؤدي إلى التفكير في الانتحار، محاولة الانتحار، أو الانتحار فعلاً)، اضطرابات ذهنية (ردود فعل ذهانية يحتمل أن تؤدي إلى التفكير في الانتحار، محاولة الانتحار، أو الانتحار فعلاً) (انظر القسم 2: الاحتياطات والتحذيرات).</li><li>انخفاض حساسية الجلد، رجفان، الصداع النصفي، اضطراب في حاسة الشم (اضطرابات الشم).</li><li>طنين في الأذن، ضعف في السمع.</li><li>الإغماء، التهاب الأوعية الدموية (التهاب وعائي).</li><li>ضيق في التنفس بما في ذلك أعراض تشبه الربو.</li><li>التهاب البنكرياس.</li><li>التهاب الكبد، موت خلايا الكبد (نخر الكبد) وهو ما قد يؤدي في حالات نادرة إلى فشل في الكبد يهدد الحياة (انظر القسم 2: الاحتياطات والتحذيرات)</li><li>الحساسية للضوء (انظر القسم 2: الاحتياطات والتحذيرات)، نزيف خفيف، أسفل الجلد يشبه حجمه رأس الدبوس (حبرات).</li><li>دم أو بلورات في البول، التهاب المسالك البولية.</li><li>فرط التعرق.</li><li>ارتفاع مستوى إنزيم الأميلاز.</li></ul><p><strong>نادرة جدًا (قد تؤثر على ما يصل إلى شخص واحد من كل 10000&nbsp;شخص)</strong></p><ul dir="rtl"><li>حالة خاصة من انخفاض عدد كريات الدم الحمراء (فقر الدم الانحلالي)؛ انخفاض خطير في أحد أنواع كريات الدم البيضاء (ندرة المحببات) (انظر القسم 2: الاحتياطات والتحذيرات).</li><li>رد فعل تحسسي يُطلق عليه تفاعل شبيه بداء المصل (انظر القسم 2: الاحتياطات والتحذيرات).</li><li>اضطراب في تنسيق الحركة، عدم الثبات أثناء المشي (اضطراب المشية)، ضغط على الدماغ (ضغط داخل القحف وورم مخي كاذب).</li><li>تشوش في رؤية الألوان.</li><li>حالات مختلفة من الطفح والبثور الجلدية.</li><li>تدهور أعراض مرض الوهن العضلي الوبيل (انظر القسم 2: الاحتياطات والتحذيرات).</li><li>التعب.</li><li>خلل في الذاكرة.</li></ul><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير تكرارها من البيانات المتوفرة)</strong></p><ul dir="rtl"><li>متلازمة مصاحبة لضعف إفراز الماء وانخفاض مستويات الصوديوم.</li><li>الشعور بحماس كبير (هوس) أو الشعور بتفاؤل كبير ونشاط زائد (الهوس الخفيف).</li><li>سرعة غير طبيعية في نظم القلب، عدم انتظام نظم القلب بشكل يهدد الحياة، تغيّر في نظم القلب (يطلق عليها &rsquo;إطالة فترة QT&lsquo;، تظهر على التخطيط الكهربائي للقلب، وهو تسجيل لنشاط كهربائية القلب).</li><li>التأثير على تجلط الدم (لدى المرضى الذين يُعالجون بمضادات فيتامين ك).</li><li>فقدان الوعي نتيجة لانخفاض حاد في مستويات سكر الدم (غيبوبة نقص سكر الدم). انظر القسم 2: الاحتياطات والتحذيرات.</li></ul><p dir="RTL">تم ربط استخدام المضادات الحيوية الكينولون والفلوروكينولون بحالات نادرة جداً تدوم طويلاً (تستمر لأشهر أو سنوات) أو ردود فعل عكسية دائمة للدواء، مثل التهاب الأوتار، تمزق الأوتار، ألم المفاصل، ألم في الأطراف، صعوبة في المشي، أحاسيس غير طبيعية مثل الإبر والدبابيس، نخز، دغدغة، حرق، تنميل أو ألم (اعتلال عصبي)، اكتئاب، تعب، اضطرابات في النوم، اعتلال في الذاكرة، واضطرابات في السمع، الرؤية، والتذوق والشم، وفي بعض الحالات بغض النظر عن عوامل الخطر الموجودة مسبقاً.&nbsp;</p><p dir="RTL">تم الإبلاغ عن حالات تضخم وضعف في جدار الأبهر أو تمزق في جدار الأبهر (أمّ الدم والتسلخ)، والتي قد تكون ممزقة وقد تكون قاتلة، وتسريب في صمامات القلب لدى المرضى الذين يتلقون الفلوروكينولونات. انظر أيضًا القسم 2: الاحتياطات والتحذيرات</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة أقل من 25˚ مئوية. تجنب التبريد أو التجميد.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء والتبخر.</p><p dir="RTL">للاستخدام لمرة واحدة فقط. يستخدم مباشرة بعد الفتح لأول مرة.</p><p dir="RTL">تم إثبات الاستقرار الكيميائي والفيزيائي خلال فترة الاستخدام وذلك لمدة 24 ساعة عند درجة حرارة الغرفة (25&deg; مئوية).</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. هذه الإجراءات ستساعد في الحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي سيبروفلوكساسين.</p><p dir="RTL">يحتوي كل 200 مللتر من سيفلوكس 400 ملغم/200 مللتر محلول للتسريب على 400 ملغم سيبروفلوكساسين.&nbsp;</p><p dir="RTL">المواد الأخرى المستخدمة في التركيبة التصنيعية هي حمض اللاكتيك، كلوريد الصوديوم، حمض الهيدروكلوريك وماء معد للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيفلوكس 400 ملغم/200 مللتر محلول للتسريب هو محلول صافٍ عديم اللون مائل إلى الأصفر قليلاً في أكياس من متعدد البروبيلين بحجم 250 مللتر مغلقة بغطاء قابل للنزع.</p><p dir="RTL">حجم العبوة: كيس واحد (200 مللتر).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك رخصة التسويق </strong></p><p dir="RTL">شركة الجزيرة للصناعات الدوائية<br />طريق الخرج<br />صندوق بريد 106229<br />الرياض 11666، المملكة العربية السعودية<br />هاتف: 8107023 (11-966) +، 2142472 (11-966) +<br />فاكس: 2078170 (11-966) +<br />البريد الإلكتروني: SAPV@hikma.com</p><p dir="RTL"><strong>الشركة المصنعة</strong><strong> </strong></p><p dir="RTL">شركة أدوية الحكمة (البرتغال)، المساهمة العامة المحدودة</p><p dir="RTL">إسترادا دو ريو دا مو،</p><p dir="RTL">مبنى رقم &deg;8, 8A e 8B، فارفانسا</p><p dir="RTL">906-2705 تيروجيم</p><p dir="RTL">سنترا، البرتغال</p><p dir="RTL">هاتف: 19608410 (2-351) +</p><p dir="RTL">فاكس: 19615102 (2-351) +<br /><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; دول الخليج العربي الأخرى</p><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 10/2023؛ رقم النسخة .SA2.0


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ciflox 400 mg/200 ml Solution for Infusion 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 200 ml contains 400 mg ciprofloxacin.
Excipient with known effect: Sodium. 
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for infusion.

Clear colourless to slightly yellow solution. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ciflox solution for infusion is indicated for the treatment of the following infections (see sections 4.4 and 5.1). Special attention should be paid to available information on resistance to ciprofloxacin before commencing therapy.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial</p><p>agents.</p><p><strong>Adults</strong></p><ul><li>Lower respiratory tract infections due to Gram-negative bacteria<ul><li>Exacerbation of chronic obstructive pulmonary disease.<br />In exacerbation of chronic obstructive pulmonary disease Ciflox should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections.</li><li>Broncho-pulmonary infections in cystic fibrosis or in bronchiectasis</li><li>Pneumonia</li></ul></li><li>Chronic suppurative otitis media</li><li>Acute exacerbation of chronic sinusitis especially if these are caused by Gram-negative bacteria</li><li>Urinary tract infections<ul><li>Acute pyelonephritis</li><li>Complicated pyelonephritis</li></ul></li><li>Bacterial prostatitis</li><li>Genital tract infections<ul><li>Epididymo-orchitis including cases due to susceptible <em>Neisseria gonorrhoeae</em></li><li>Pelvic inflammatory disease including cases due to susceptible <em>Neisseria gonorrhoeae</em></li></ul></li><li>Infections of the gastrointestinal tract (e.g. travellers` diarrhoea)</li><li>Intra-abdominal infections</li><li>Infections of the skin and soft tissue caused by Gram-negative bacteria</li><li>Malignant external otitis</li><li>Infections of the bones and joints</li><li>Inhalation anthrax (post-exposure prophylaxis and curative treatment)</li></ul><p>Ciprofloxacin may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p><strong>Children and adolescents</strong></p><ul><li>Broncho-pulmonary infections due to <em>Pseudomonas aeruginosa </em>in patients with cystic fibrosis</li><li>Complicated urinary tract infections and acute pyelonephritis</li><li>Inhalation anthrax (post-exposure prophylaxis and curative treatment)</li></ul><p>Ciprofloxacin may also be used to treat severe infections in children and adolescents when this is considered to be necessary.</p><p>Treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents (see sections 4.4 and 5.1)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Posology</em></strong></p><p>The dosage is determined by the indication, the severity and the site of the infection, the susceptibility to ciprofloxacin of the causative organism(s), the renal function of the patient and, in children and adolescents the body weight.</p><p>The duration of treatment depends on the severity of the illness and on the clinical and bacteriological course.</p><p>After intravenous initiation of treatment, the treatment can be switched to oral treatment with</p><p>tablet or suspension if clinically indicated at the discretion of the physician. IV treatment should be followed by oral route as soon as possible.</p><p>In severe cases or if the patient is unable to take tablets (e.g. patients on enteral nutrition), it is</p><p>recommended to commence therapy with intravenous ciprofloxacin until a switch to oral administration is possible.</p><p>Treatment of infections due to certain bacteria (e.g. <em>Pseudomonas aeruginosa</em>, <em>Acinetobacter </em>or <em>Staphylococci</em>) may require higher ciprofloxacin doses and co-administration with other<em> </em>appropriate antibacterial agents.</p><p>Treatment of some infections (e.g. pelvic inflammatory disease, intra-abdominal infections, infections in neutropenic patients and infections of bones and joints) may require coadministration with other appropriate antibacterial agents depending on the pathogens involved.</p><p><strong>Adults</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top; width:493px"><p>Indications</p></td><td style="vertical-align:top; width:277px"><p>Daily dose in mg</p></td><td style="vertical-align:top; width:260px"><p>Total duration of treatment (including switch to oral</p><p>therapy as soon as possible)</p></td></tr><tr><td colspan="2" style="vertical-align:top; width:493px"><p>Infections of the lower respiratory tract</p></td><td style="vertical-align:top; width:277px"><p>400 mg twice daily to 400 mg three times a day</p></td><td style="vertical-align:top; width:260px"><p>7 to 14 days</p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:225px"><p>Infections of the upper respiratory tract</p></td><td style="vertical-align:top; width:268px"><p>Acute exacerbation of chronic sinusitis</p></td><td style="vertical-align:top; width:277px"><p>400 mg twice daily to 400 mg three times a day</p></td><td style="vertical-align:top; width:260px"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top; width:268px"><p>Chronic suppurative otitis media</p></td><td style="vertical-align:top; width:277px"><p>400 mg twice daily to 400 mg three times a day</p></td><td style="vertical-align:top; width:260px"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top; width:268px"><p>Malignant external otitis</p></td><td style="vertical-align:top; width:277px"><p>400 mg three times a day</p></td><td style="vertical-align:top; width:260px"><p>28 days up to 3 months</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:225px"><p>Urinary tract infections (see section 4.4)</p></td><td style="vertical-align:top; width:268px"><p>Acute and complicated pyelonephritis</p></td><td style="vertical-align:top; width:277px"><p>400 mg twice daily to 400 mg three times a day</p></td><td style="vertical-align:top; width:260px"><p>7 to 21 days, it can be continued for longer than 21 days in some specific circumstances (such as abscesses)</p></td></tr><tr><td style="vertical-align:top; width:268px"><p>Bacterial prostatitis</p></td><td style="vertical-align:top; width:277px"><p>400 mg twice daily to 400 mg three times a day</p></td><td style="vertical-align:top; width:260px"><p>2 to 4 weeks (acute)</p></td></tr><tr><td style="vertical-align:top; width:225px"><p>Genital tract infections</p></td><td style="vertical-align:top; width:268px"><p>Epididymo-orchitis and pelvic inflammatory diseases including cases due to susceptible <em>Neiserria gonorrhoeae</em></p></td><td style="vertical-align:top; width:277px"><p>400 mg twice daily to 400 mg three times a day</p></td><td style="vertical-align:top; width:260px"><p>at least 14 days</p></td></tr><tr><td rowspan="5" style="vertical-align:top; width:225px"><p>Infections of the gastro-intestinal tract and intraabdominal infections</p></td><td style="vertical-align:top; width:268px"><p>Diarrhoea caused by bacterial pathogens including <em>Shigella&nbsp;</em>spp. other than&nbsp;<em>Shigella dysenteriae&nbsp;</em>type 1 and empirical treatment of severe travellers&#39; diarrhoea</p></td><td style="vertical-align:top; width:277px"><p>400 mg twice daily</p></td><td style="vertical-align:top; width:260px"><p>1 day</p></td></tr><tr><td style="vertical-align:top; width:268px"><p>Diarrhoea caused by&nbsp;<em>Shigella dysenteriae&nbsp;</em>type 1</p></td><td style="vertical-align:top; width:277px"><p>400 mg twice daily</p></td><td style="vertical-align:top; width:260px"><p>5 days</p></td></tr><tr><td style="vertical-align:top; width:268px"><p>Diarrhoea caused by&nbsp;<em>Vibrio cholerae</em></p></td><td style="vertical-align:top; width:277px"><p>400 mg twice daily</p></td><td style="vertical-align:top; width:260px"><p>3 days</p></td></tr><tr><td style="vertical-align:top; width:268px"><p>Typhoid fever</p></td><td style="vertical-align:top; width:277px"><p>400 mg twice daily</p></td><td style="vertical-align:top; width:260px"><p>7 days</p></td></tr><tr><td style="vertical-align:top; width:268px"><p>Intra-abdominal infections due to Gram-negative bacteria</p></td><td style="vertical-align:top; width:277px"><p>400 mg twice daily to 400 mg three times a day</p></td><td style="vertical-align:top; width:260px"><p>5 to 14 days</p></td></tr><tr><td style="vertical-align:top; width:225px"><p>Infections of the skin and soft tissue caused by Gram-negative bacteria</p></td><td colspan="2" style="vertical-align:top; width:545px"><p>400 mg twice daily to 400 mg three times a day</p></td><td style="vertical-align:top; width:260px"><p>7 to 14 days</p></td></tr><tr><td style="vertical-align:top; width:225px"><p>Bone and joint infections</p></td><td colspan="2" style="vertical-align:top; width:545px"><p>400 mg twice daily to 400 mg three times a day</p></td><td style="vertical-align:top; width:260px"><p>max. of 3 months</p></td></tr><tr><td style="vertical-align:top; width:225px"><p>Neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p>Ciprofloxacin should be coadministered with appropriate antibacterial agent(s) in accordance to official guidance.</p></td><td colspan="2" style="vertical-align:top; width:545px"><p>400 mg twice daily to 400 mg three times a day</p></td><td style="vertical-align:top; width:260px"><p>Therapy should be continued over the entire period of</p><p>neutropenia</p></td></tr><tr><td style="vertical-align:top; width:225px"><p>Inhalation anthrax post-exposure prophylaxis and curative treatment for persons requiring parenteral treatment</p><p>Drug administration should begin as soon as possible after suspected or confirmed exposure.</p></td><td colspan="2" style="vertical-align:top; width:545px"><p>400 mg twice daily</p></td><td style="vertical-align:top; width:260px"><p>60 days from the confirmation of <em>Bacillus anthracis </em>exposure</p></td></tr></tbody></table><p><strong>Paediatric population</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top; width:316px"><p>Indication</p></td><td style="vertical-align:top; width:422px"><p>Daily dose in mg</p></td><td style="vertical-align:top"><p>Total duration of treatment (including switch to oral therapy as soon as possible)</p></td></tr><tr><td style="vertical-align:top; width:316px"><p>Cystic fibrosis</p></td><td style="vertical-align:top; width:422px"><p>10 mg/kg body weight three times a day with a maximum of 400 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 14 days</p></td></tr><tr><td style="vertical-align:top; width:316px"><p>Complicated urinary tract infections and acute pyelonephritis</p></td><td style="vertical-align:top; width:422px"><p>6 mg/kg body weight three times a day to 10 mg/kg body weight three times a day with a maximum of 400 mg per dose.</p></td><td style="vertical-align:top"><p>10 to 21 days</p></td></tr><tr><td style="vertical-align:top; width:316px"><p>Inhalation anthrax post-exposure curative treatment for persons requiring parenteral treatment</p><p>Drug administration should begin as soon as possible after suspected or confirmed exposure</p></td><td style="vertical-align:top; width:422px"><p>10 mg/kg body weight twice daily to 15 mg/kg body weight twice daily with a maximum of 400 mg per dose.</p></td><td style="vertical-align:top"><p>60 days from the confirmation of <em>Bacillus anthracis </em>exposure</p></td></tr><tr><td style="vertical-align:top; width:316px"><p>Other severe</p><p>infections</p></td><td style="vertical-align:top; width:422px"><p>10 mg/kg body weight three times a day with a maximum of 400 mg per dose.</p></td><td style="vertical-align:top"><p>According to the type of infections</p></td></tr></tbody></table><p><strong>Elderly patients</strong></p><p>Elderly patients should receive a dose selected according to the severity of the infection and the patient`s creatinine clearance.</p><p><strong>Patients with renal and hepatic impairment</strong></p><p>Recommended starting and maintenance doses for patients with impaired renal function:</p><table border="1" cellspacing="0" cellpadding="0" style="width:870px"><tbody><tr><td style="vertical-align:top; width:234px"><p><strong>Creatinine Clearance</strong><strong> </strong><strong>[ml/min/1.73 m&sup2;]</strong></p></td><td style="vertical-align:top; width:201px"><p><strong>Serum Creatinine</strong><strong> </strong><strong>[&mu;mol/L]</strong></p></td><td style="vertical-align:top; width:434px"><p><strong>Intravenous Dose</strong><strong> </strong><strong>[mg]</strong></p></td></tr><tr><td style="vertical-align:top; width:234px"><p>&gt; 60</p></td><td style="vertical-align:top; width:201px"><p>&lt; 124</p></td><td style="vertical-align:top; width:434px"><p>See Usual Dosage.</p></td></tr><tr><td style="vertical-align:top; width:234px"><p>30-60</p></td><td style="vertical-align:top; width:201px"><p>124 to 168</p></td><td style="vertical-align:top; width:434px"><p>200-400 mg every 12 h</p></td></tr><tr><td style="vertical-align:top; width:234px"><p>&lt; 30</p></td><td style="vertical-align:top; width:201px"><p>&gt; 169</p></td><td style="vertical-align:top; width:434px"><p>200-400 mg every 24 h</p></td></tr><tr><td style="vertical-align:top; width:234px"><p>Patients on haemodialysis</p></td><td style="vertical-align:top; width:201px"><p>&gt; 169</p></td><td style="vertical-align:top; width:434px"><p>200-400 mg every 24 h (after dialysis)</p></td></tr><tr><td style="vertical-align:top; width:234px"><p>Patients on peritoneal dialysis</p></td><td style="vertical-align:top; width:201px"><p>&gt; 169</p></td><td style="vertical-align:top; width:434px"><p>200-400 mg every 24 h</p></td></tr></tbody></table><p>In patients with impaired liver function no dose adjustment is required.</p><p>Dosing in children with impaired renal and/or hepatic function has not been studied.</p><p><strong><em>Method of administration</em></strong></p><p>Ciprofloxacin solution for infusion should be checked visually prior to use. It must not be used if cloudy.</p><p>Ciprofloxacin should be administered by intravenous infusion. For children, the infusion duration is 60 minutes.</p><p>In adult patients, infusion time is 60 minutes for 400 mg Ciprofloxacin solution for infusion. Slow infusion into a large vein will minimise patient discomfort and reduce the risk of venous irritation.</p><p>The infusion solution can be infused either directly or after mixing with other compatible infusion solutions (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance, to other quinolones or to any of the excipients listed in section 6.1.
•	Concomitant administration of ciprofloxacin and tizanidine (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of Ciprofloxacin should be avoided in patients who have experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products (see section 4.8). Treatment of these patients with Ciprofloxacin should only be initiated in the absence of alternative treatment options and after careful benefit/risk assessment (see section 4.3).</p><p><strong>Severe infections and mixed infections with Gram-positive and anaerobic pathogens</strong></p><p>Ciprofloxacin monotherapy is not suited for treatment of severe infections and infections that might be due to Gram-positive or anaerobic pathogens. In such infections ciprofloxacin must be co-administered with other appropriate antibacterial agents.</p><p><strong>Streptococcal Infections (including <em>Streptococcus pneumoniae</em>)</strong></p><p>Ciprofloxacin is not recommended for the treatment of streptococcal infections due to inadequate efficacy.</p><p><strong>Genital tract infections</strong></p><p>Epididymo-orchitis and pelvic inflammatory diseases may be caused by fluoroquinolone-resistant&nbsp;<em>Neisseria gonorrhoeae</em>&nbsp;isolates.</p><p>For epididymo-orchitis and pelvic inflammatory diseases, empirical ciprofloxacin should only be considered in combination with another appropriate antibacterial agent (e.g. a cephalosporin) unless ciprofloxacin-resistant&nbsp;<em>Neisseria gonorrhoeae</em>&nbsp;can be excluded. If clinical improvement is not achieved after 3 days of treatment, the therapy should be reconsidered.</p><p><strong>Urinary tract infections</strong></p><p>Resistance to fluoroquinolones of&nbsp;<em>Escherichia coli</em>&nbsp;&ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in&nbsp;<em>Escherichia coli</em>&nbsp;to fluoroquinolones.</p><p><strong>Intra-abdominal infections</strong></p><p>There are limited data on the efficacy of ciprofloxacin in the treatment of post-surgical intra-abdominal infections.</p><p><strong>Travellers&#39; diarrhoea</strong></p><p>The choice of ciprofloxacin should take into account information on resistance to ciprofloxacin in relevant pathogens in the countries visited.</p><p><strong>Infections of the bones and joints</strong></p><p>Ciprofloxacin should be used in combination with other antimicrobial agents depending on the results of the microbiological documentation.</p><p><strong>Inhalational anthrax</strong></p><p>Use in humans is based on&nbsp;<em>in-vitro</em>&nbsp;susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and /or international consensus documents regarding the treatment of anthrax.</p><p><strong>Paediatric population</strong></p><p>The use of ciprofloxacin in children and adolescents should follow available official guidance.</p><p>Ciprofloxacin treatment should be initiated only by physicians who are experienced in the treatment of cystic fibrosis and/or severe infections in children and adolescents.</p><p>Ciprofloxacin has been shown to cause arthropathy in weight-bearing joints of immature animals. Safety data from a randomised double-blind study on ciprofloxacin use in children (ciprofloxacin: n=335, mean age = 6.3 years; comparators: n=349, mean age = 6.2 years; age range = 1 to 17 years) revealed an incidence of suspected drug-related arthropathy (discerned from joint-related clinical signs and symptoms) by Day +42 of 7.2% and 4.6%. Respectively, an incidence of drug-related arthropathy by 1-year follow-up was 9.0% and 5.7%. The increase of suspected drug-related arthropathy cases over time was not statistically significant between groups. Treatment should be initiated only after a careful benefit/risk evaluation, due to possible adverse events related to joints and/or surrounding tissue (see section 4.8).</p><p><strong>Broncho-pulmonary infections in cystic fibrosis</strong></p><p>Clinical trials have included children and adolescents aged 5-17 years. More limited experience is available in treating children between 1 and 5 years of age.</p><p><strong>Complicated urinary tract infections and pyelonephritis</strong></p><p>Ciprofloxacin treatment of urinary tract infections should be considered when other treatments cannot be used, and should be based on the results of the microbiological documentation.</p><p>Clinical trials have included children and adolescents aged 1-17 years.</p><p><strong>Other specific severe infections</strong></p><p>Other severe infections in accordance with official guidance, or after careful benefit-risk evaluation when other treatments cannot be used, or after failure to conventional therapy and when the microbiological documentation can justify a ciprofloxacin use.</p><p>The use of ciprofloxacin for specific severe infections other than those mentioned above has not been evaluated in clinical trials and the clinical experience is limited. Consequently, caution is advised when treating patients with these infections.</p><p><strong>Hypersensitivity</strong></p><p>Hypersensitivity and allergic reactions, including anaphylaxis and anaphylactoid reactions, may occur following a single dose (see section 4.8) and may be life-threatening. If such reaction occurs, ciprofloxacin should be discontinued and an adequate medical treatment is required.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p><p><strong>Prolonged, disabling and potentially irreversible serious adverse drug reactions</strong></p><p>Very rare cases of prolonged (continuing months or years), disabling and potentially irreversible serious adverse drug reactions affecting different, sometimes multiple, body systems (musculoskeletal, nervous, psychiatric and senses) have been reported in patients receiving quinolones and fluoroquinolones irrespective of their age and pre-existing risk factors. Ciprofloxacin should be discontinued immediately at the first signs or symptoms of any serious adverse reaction and patients should be advised to contact their prescriber for advice.</p><p><strong>Tendinitis and tendon rupture</strong></p><p>Ciprofloxacin should generally not be used in patients with a history of tendon disease/disorder related to quinolone treatment. Nevertheless, in very rare instances, after microbiological documentation of the causative organism and evaluation of the risk/benefit balance, ciprofloxacin may be prescribed to these patients for the treatment of certain severe infections, particularly in the event of failure of the standard therapy or bacterial resistance, where the microbiological data may justify the use of ciprofloxacin.</p><p>Tendinitis and tendon rupture (especially but not limited to Achilles tendon), sometimes bilateral, may as early as within 48 hours of starting treatment with quinolones and fluoroquinolones and have been reported to occur even up to several months after discontinuation of treatment (see section 4.8). The risk of tendinitis and tendon rupture is increased in older patients, patients with renal impairment, patients with solid organ transplants, and those treated concurrently with corticosteroids. Therefore, concomitant use of corticosteroids should be avoided.</p><p>At the first sign of tendinitis (e.g. painful swelling, inflammation) the treatment with Ciprofloxacin should be discontinued and alternative treatment should be considered. The affected limb(s) should be appropriately treated (immobilisation). Corticosteroids should not be used if signs of tendinopathy occur.</p><p><strong>Patients with myasthenia gravis</strong></p><p>Ciprofloxacin should be used with caution in patients with myasthenia gravis, because symptoms can be exacerbated (see section 4.8).</p><p><strong>Aortic aneurysm and dissection, and heart valve regurgitation/incompetence</strong></p><p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection, particularly in elderly patients, and of aortic and mitral valve regurgitation after intake of fluoroquinolones. Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.8).</p><p>Therefore, fluoroquinolones should only be used after a careful benefit/risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease or congenital heart valve disease, or in patients diagnosed with pre-existing aortic aneurysm and/or dissection or heart valve disease, or in presence of other risk factors or conditions predisposing:</p><ul><li>For both aortic aneurysm and dissection and heart valve regurgitation/incompetence (e.g. connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, Turner syndrome, Behcet&#39;s disease, hypertension, rheumatoid arthritis) or additionally</li><li>For aortic aneurysm and dissection (e.g. vascular disorders such as Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sj&ouml;gren&#39;s syndrome) or additionally</li><li>For heart valve regurgitation/incompetence (e.g. infective endocarditis).</li></ul><p>The risk of aortic aneurysm and dissection, and their rupture may also be increased in patients treated concurrently with systemic corticosteroids.</p><p>In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p><p>Patients should be advised to seek immediate medical attention in case of acute dyspnoea, new onset of heart palpitations, or development of oedema of the abdomen or lower extremities.</p><p><strong>Vision disorders</strong></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately.</p><p><strong>Photosensitivity</strong></p><p>Ciprofloxacin has been shown to cause photosensitivity reactions. Patients taking ciprofloxacin should be advised to avoid direct exposure to either extensive sunlight or UV irradiation during treatment (see section 4.8).</p><p><strong>Seizures</strong></p><p>Ciprofloxacin like other quinolones are known to trigger seizures or lower the seizure threshold. Cases of status epilepticus have been reported. Ciprofloxacin should be used with caution in patients with CNS disorders which may be predisposed to seizure. If seizures occur ciprofloxacin should be discontinued (see section 4.8).</p><p><strong>Peripheral neuropathy</strong></p><p>Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesia, hypoaesthesia, dysaesthesia, or weakness have been reported in patients receiving quinolones and fluoroquinolones. Patients under treatment with Ciprofloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition (see section 4.8).</p><p><strong>Psychiatric reactions</strong></p><p>Psychiatric reactions may occur even after first administration of ciprofloxacin. In rare cases, depression or psychosis can progress to suicidal ideations/thoughts culminating in attempted suicide or completed suicide. In the occurrence of such cases, ciprofloxacin should be discontinued.</p><p><strong>Cardiac disorders</strong></p><p>Caution should be taken when using fluoroquinolones, including ciprofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><ul><li>Congenital long QT syndrome.</li><li>Concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</li><li>Uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia).</li><li>Cardiac disease (e.g. heart failure, myocardial infarction, bradycardia).</li></ul><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including ciprofloxacin, in these populations. (See section 4.2 Elderly patients, section 4.5, section 4.8, section 4.9).</p><p><strong>Dysglycaemia</strong></p><p>As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported (see section 4.8), usually in elderly diabetic patients, receiving concomitant treatment with an oral hypoglycaemic agent (e.g. glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended.</p><p><strong>Gastrointestinal System</strong></p><p>The occurrence of severe and persistent diarrhoea during or after treatment (including several weeks after treatment) may indicate an antibiotic-associated colitis (life-threatening with possible fatal outcome), requiring immediate treatment (see section 4.8). In such cases, ciprofloxacin should immediately be discontinued, and an appropriate therapy initiated. Anti-peristaltic drugs are contraindicated in this situation.</p><p><strong>Renal and urinary system</strong></p><p>Crystalluria related to the use of ciprofloxacin has been reported (see section 4.8). Patients receiving ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided.</p><p><strong>Impaired renal function</strong></p><p>Since ciprofloxacin is largely excreted unchanged via renal pathway dose adjustment is needed in patients with impaired renal function as described in section 4.2 to avoid an increase in adverse drug reactions due to accumulation of ciprofloxacin.</p><p><strong>Hepatobiliary system</strong></p><p>Cases of hepatic necrosis and life-threatening hepatic failure have been reported with ciprofloxacin (see section 4.8). In the event of any signs and symptoms of hepatic disease (such as anorexia, jaundice, dark urine, pruritus, or tender abdomen), treatment should be discontinued.</p><p><strong>Glucose-6-phosphate dehydrogenase deficiency</strong></p><p>Haemolytic reactions have been reported with ciprofloxacin in patients with glucose-6-phosphate dehydrogenase deficiency. Ciprofloxacin should be avoided in these patients unless the potential benefit is considered to outweigh the possible risk. In this case, potential occurrence of haemolysis should be monitored.</p><p><strong>Resistance</strong></p><p>During or following a course of treatment with ciprofloxacin bacteria that demonstrate resistance to ciprofloxacin may be isolated, with or without a clinically apparent superinfection. There may be a particular risk of selecting for ciprofloxacin-resistant bacteria during extended durations of treatment and when treating nosocomial infections and/or infections caused by&nbsp;<em>Staphylococcus</em>&nbsp;and&nbsp;<em>Pseudomonas species</em>.</p><p><strong>Cytochrome P450</strong></p><p>Ciprofloxacin inhibits CYP1A2 and thus may cause increased serum concentration of concomitantly administered substances metabolised by this enzyme (e.g. theophylline, clozapine, olanzapine, ropinirole, tizanidine, duloxetine, agomelatine). Therefore, patients taking these substances concomitantly with ciprofloxacin should be monitored closely for clinical signs of overdose, and determination of serum concentrations (e.g. of theophylline) may be necessary (see section 4.5). Co-administration of ciprofloxacin and tizanidine is contra-indicated.</p><p><strong>Methotrexate</strong></p><p>The concomitant use of ciprofloxacin with methotrexate is not recommended (see section 4.5).</p><p><strong>Interaction with tests</strong></p><p>The&nbsp;<em>in-vitro</em>&nbsp;activity of ciprofloxacin against&nbsp;<em>Mycobacterium tuberculosis</em>&nbsp;might give false negative bacteriological test results in specimens from patients currently taking ciprofloxacin.</p><p><strong>Injection Site Reaction</strong></p><p>Local intravenous site reactions have been reported with the intravenous administration of ciprofloxacin. These reactions are more frequent if the infusion time is 30 minutes or less. These may appear as local skin reactions which resolve rapidly upon completion of the infusion. Subsequent intravenous administration is not contraindicated unless the reactions recur or worsen.</p><p><strong>Ciflox</strong><strong> </strong><strong>contains sodium</strong></p><p>Ciflox contains sodium. Each 200 ml of Ciflox 400 mg/200 ml Solution for Infusion contains 30.8 mmol (708.4 mg) sodium, equivalent to 35.42% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Effects of other products on ciprofloxacin:</em></strong></p><p><strong>Drugs known to prolong QT interval</strong></p><p>Ciprofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong QT interval (e.g. Class IA and III anti-arrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4).</p><p><strong>Probenecid</strong></p><p>Probenecid interferes with renal secretion of ciprofloxacin. Co-administration of probenecid and ciprofloxacin increases ciprofloxacin serum concentrations.</p><p><strong><em>Effects of ciprofloxacin on other medicinal products:</em></strong></p><p><strong>Tizanidine</strong></p><p>Tizanidine must not be administered together with ciprofloxacin (see section 4.3). In a clinical study with healthy subjects, there was an increase in serum tizanidine concentration (C<sub>max</sub>&nbsp;increase: 7-fold, range: 4 to 21-fold; AUC increase: 10-fold, range: 6 to 24-fold) when given concomitantly with ciprofloxacin. Increased serum tizanidine concentration is associated with a potentiated hypotensive and sedative effect.</p><p><strong>Methotrexate</strong></p><p>Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of methotrexate-associated toxic reactions. The concomitant use is not recommended (see section 4.4).</p><p><strong>Theophylline</strong></p><p>Concurrent administration of ciprofloxacin and theophylline can cause an undesirable increase in serum theophylline concentration. This can lead to theophylline-induced side effects that may rarely be life threatening or fatal. During the combination, serum theophylline concentrations should be checked and the theophylline dose reduced as necessary (see section 4.4).</p><p><strong>Other xanthine derivatives</strong></p><p>On concurrent administration of ciprofloxacin and caffeine or pentoxifylline (oxpentifylline), raised serum concentrations of these xanthine derivatives were reported.</p><p><strong>Phenytoin</strong></p><p>Simultaneous administration of ciprofloxacin and phenytoin may result in increased or reduced serum levels of phenytoin such that monitoring of drug levels is recommended.</p><p><strong>Cyclosporin</strong></p><p>A transient rise in the concentration of serum creatinine was observed when ciprofloxacin and cyclosporin containing medicinal products were administered simultaneously. Therefore, it is frequently (twice a week) necessary to control the serum creatinine concentrations in these patients.</p><p><strong>Vitamin K antagonists</strong></p><p>Simultaneous administration of ciprofloxacin with a vitamin K antagonist may augment its anti-coagulant effects. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of ciprofloxacin to the increase in INR (international normalised ratio) is difficult to assess. The INR should be monitored frequently during and shortly after co-administration of ciprofloxacin with a vitamin K antagonist (e.g., warfarin, acenocoumarol, phenprocoumon, or fluindione).</p><p><strong>Duloxetine</strong></p><p>In clinical studies, it was demonstrated that concomitant use of duloxetine with strong inhibitors of the CYP450 1A2 isozyme such as fluvoxamine, may result in an increase of AUC and C<sub>max</sub>&nbsp;of duloxetine. Although no clinical data are available on a possible interaction with ciprofloxacin, similar effects can be expected upon concomitant administration (see section 4.4).</p><p><strong>Ropinirole</strong></p><p>It was shown in a clinical study that concomitant use of ropinirole with ciprofloxacin, a moderate inhibitor of the CYP450 1A2 isozyme, results in an increase of C<sub>max</sub>&nbsp;and AUC of ropinirole by 60% and 84%, respectively. Monitoring of ropinirole-related side effects and dose adjustment as appropriate is recommended during and shortly after co-administration with ciprofloxacin (see section 4.4).</p><p><strong>Lidocaine</strong></p><p>It was demonstrated in healthy subjects that concomitant use of lidocaine containing medicinal products with ciprofloxacin, a moderate inhibitor of CYP450 1A2 isozyme, reduces clearance of intravenous lidocaine by 22%. Although lidocaine treatment was well tolerated, a possible interaction with ciprofloxacin associated with side effects may occur upon concomitant administration.</p><p><strong>Clozapine</strong></p><p>Following concomitant administration of 250 mg ciprofloxacin with clozapine for 7 days, serum concentrations of clozapine and N-desmethylclozapine were increased by 29% and 31%, respectively. Clinical surveillance and appropriate adjustment of clozapine dosage during and shortly after co-administration with ciprofloxacin are advised (see section 4.4).</p><p><strong>Sildenafil</strong></p><p>C<sub>max</sub>&nbsp;and AUC of sildenafil were increased approximately twofold in healthy subjects after an oral dose of 50 mg given concomitantly with 500 mg ciprofloxacin. Therefore, caution should be used prescribing ciprofloxacin concomitantly with sildenafil taking into consideration the risks and the benefits.</p><p><strong>Agomelatine</strong></p><p>In clinical studies, it was demonstrated that fluvoxamine, as a strong inhibitor of the CYP450 1A2 isoenzyme, markedly inhibits the metabolism of agomelatine resulting in a 60-fold increase of agomelatine exposure. Although no clinical data are available for a possible interaction with ciprofloxacin, a moderate inhibitor of CYP450 1A2, similar effects can be expected upon concomitant administration (see section 4.4).</p><p><strong>Zolpidem</strong></p><p>Co-administration of ciprofloxacin may increase blood levels of zolpidem, concurrent use is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>The data that are available on administration of ciprofloxacin to pregnant women indicates no malformative or feto/neonatal toxicity of ciprofloxacin. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. In juvenile and prenatal animals exposed to quinolones, effects on immature cartilage have been observed, thus, it cannot be excluded that the drug could cause damage to articular cartilage in the human immature organism / foetus (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of ciprofloxacin during pregnancy.</p><p><strong>Breast-feeding</strong></p><p>Ciprofloxacin is excreted in breast milk. Due to the potential risk of articular damage, ciprofloxacin should not be used during breast-feeding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Due to its neurological effects, ciprofloxacin may affect reaction time. Thus, the ability to drive or to operate machinery may be impaired.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions (ADRs) are nausea, diarrhoea, vomiting, transient increase in transaminases, rash, and injection and infusion site reactions.</p><p>ADRs derived from clinical studies and post-marketing surveillance with Ciprofloxacin (oral, intravenous and sequential therapy) sorted by categories of frequency are listed below. The frequency analysis takes into account data from both oral and intravenous administration of ciprofloxacin.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p>&ge; 1/100 to &lt; 1/10</p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p>&ge; 1/1,000 to &lt; 1/100</p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p>&ge; 1/10,000 to &lt; 1/1,000</p></td><td style="vertical-align:top"><p><strong>Very Rare</strong></p><p>&lt; 1/10,000</p></td><td style="vertical-align:top"><p><strong>Frequency not known</strong></p><p>(cannot be estimated from the available data)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and Infestations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Mycotic super-infections</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Blood and Lymphatic System Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Eosinophilia</p></td><td style="vertical-align:top"><p>Leukopenia</p><p>Anaemia</p><p>Neutropenia</p><p>Leukocytosis</p><p>Thrombocytopenia</p><p>Thrombocytaemia</p></td><td style="vertical-align:top"><p>Haemolytic anaemia</p><p>Agranulocytosis</p><p>Pancytopenia (life-threatening)</p><p>Bone marrow depression (life-threatening)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Immune System Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Allergic reaction</p><p>Allergic oedema/ angiooedema</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p><p>Anaphylactic shock (life-threatening) (see section 4.4)</p><p>Serum sickness-like reaction</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Syndrome of inappropriate secretion of antidiuretic hormone (SIADH)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and Nutrition Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Hyperglycaemia</p><p>Hypoglycaemia (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypoglycaemic coma (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric Disorders*</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Psychomotor hyperactivity/ agitation</p></td><td style="vertical-align:top"><p>Confusion and disorientation</p><p>Anxiety reaction</p><p>Abnormal dreams</p><p>Depression (potentially culminating in suicidal ideations/thoughts or suicide attempts and completed suicide) (see section 4.4)</p><p>Hallucinations</p></td><td style="vertical-align:top"><p>Psychotic reactions (potentially culminating in suicidal ideations/ thoughts or suicide attempts and completed suicide) (see section 4.4)</p></td><td style="vertical-align:top"><p>Mania, incl. hypomania</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous System Disorders*</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p><p>Sleep disorders</p><p>Taste disorders</p></td><td style="vertical-align:top"><p>Par- and Dysaesthesia</p><p>Hypoaesthesia</p><p>Tremor</p><p>Seizures (including status epilepticus see section 4.4)</p><p>Vertigo</p></td><td style="vertical-align:top"><p>Migraine</p><p>Disturbed coordination</p><p>Gait disturbance</p><p>Olfactory nerve disorders</p><p>Intracranial hypertension and pseudotumor cerebri</p></td><td style="vertical-align:top"><p>Peripheral neuropathy and polyneur-opathy (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Eye Disorders*</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Visual disturbances (e.g. diplopia)</p></td><td style="vertical-align:top"><p>Visual colour distortions</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Ear and Labyrinth Disorders*</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tinnitus</p><p>Hearing loss/ Hearing impaired</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac Disorders**</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Ventricular arrhythmia, torsades de pointes (reported predominantly in patients with risk factors for QT prolongation), ECG QT prolonged (see sections 4.4 and 4.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular Disorders**</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vasodilatation</p><p>Hypotension</p><p>Syncope</p></td><td style="vertical-align:top"><p>Vasculitis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, Thoracic and Mediastinal Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Dyspnoea (including asthmatic condition)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Gastro-intestinal Disorders</strong></p></td><td style="vertical-align:top"><p>Nausea</p><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Gastro-intestinal and abdominal pains</p><p>Dyspepsia</p><p>Flatulence</p></td><td style="vertical-align:top"><p>Antibiotic associated colitis (very rarely with possible fatal outcome) (see section 4.4)</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Increase in transaminases</p><p>Increased bilirubin</p></td><td style="vertical-align:top"><p>Hepatic impairment</p><p>Cholestatic icterus</p><p>Hepatitis</p></td><td style="vertical-align:top"><p>Liver necrosis (very rarely progressing to life-threatening hepatic failure) (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash</p><p>Pruritus</p><p>Urticaria</p></td><td style="vertical-align:top"><p>Photosensitivity reactions (see section 4.4)</p></td><td style="vertical-align:top"><p>Petechiae</p><p>Erythema multiforme</p><p>Erythema nodosum</p><p>Stevens-Johnson syndrome (potentially life-threatening)</p><p>Toxic epidermal necrolysis (potentially life-threatening)</p></td><td style="vertical-align:top"><p>Acute Generalised Exanthematous Pustulosis (AGEP)</p><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and Connective Tissue Disorders*</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Musculoskeletal pain (e.g. extremity pain, back pain, chest pain)</p><p>Arthralgia</p></td><td style="vertical-align:top"><p>Myalgia</p><p>Arthritis</p><p>Increased muscle tone and cramping</p></td><td style="vertical-align:top"><p>Muscular weakness</p><p>Tendinitis</p><p>Tendon rupture (predominantly Achilles tendon) (see section 4.4)</p><p>Exacerbation of symptoms of myasthenia gravis (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Renal and Urinary Disorders</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Renal impairment</p></td><td style="vertical-align:top"><p>Renal failure</p><p>Haematuria</p><p>Crystalluria (see section 4.4)</p><p>Tubulointerstitial nephritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>General Disorders and Administration Site Conditions*</strong></p></td><td style="vertical-align:top"><p>Injection and infusion site reactions (only intravenous administration)</p></td><td style="vertical-align:top"><p>Asthenia</p><p>Fever</p></td><td style="vertical-align:top"><p>Oedema</p><p>Sweating (hyperhidrosis)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Increase in blood alkaline phosphatase</p></td><td style="vertical-align:top"><p>Increased amylase</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>International normalised ratio increased (in patients treated with Vitamin K antagonists)</p></td></tr></tbody></table><p>*Very rare cases of prolonged (up to months or years), disabling and potentially irreversible serious drug reactions affecting several, sometimes multiple, system organ classes and senses (including reactions such as tendonitis, tendon rupture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders, and impairment of hearing, vision, taste and smell) have been reported in association with the use of quinolones and fluoroquinolones in some cases irrespective of pre-existing risk factors (see Section 4.4).</p><p>**Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.4).</p><p>The following undesirable effects have a higher frequency category in the subgroups of patients receiving intravenous or sequential (intravenous to oral) treatment:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vomiting, Transient increase in transaminases, Rash</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thrombocytopenia, Thrombocytaemia, Confusion and disorientation, Hallucinations, Par- and dysaesthesia, Seizures, Vertigo, Visual disturbances, Hearing loss, Tachycardia, Vasodilatation, Hypotension, Transient hepatic impairment, Cholestatic icterus, Renal failure, Oedema</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pancytopenia, Bone marrow depression, Anaphylactic shock, Psychotic reactions, Migraine, Olfactory nerve disorders, Hearing impaired, Vasculitis, Pancreatitis, Liver necrosis, Petechiae, Tendon rupture</p></td></tr></tbody></table><p><strong>Paediatric population</strong></p><p>The incidence of arthropathy (arthralgia, arthritis), mentioned above, is referring to data collected in studies with adults. In children, arthropathy is reported to occur commonly (see section 4.4).</p><p><strong>Reporting of suspected adverse reactions</strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https: //ade.sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States</p><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An overdose of 12 g has been reported to lead to mild symptoms of toxicity. An acute overdose of 16 g has been reported to cause acute renal failure.</p><p>Symptoms in overdose consist of dizziness, tremor, headache, tiredness, seizures, hallucinations, confusion, abdominal discomfort, renal and hepatic impairment as well as crystalluria and haematuria. Reversible renal toxicity has been reported.</p><p>Apart from routine emergency measures, ,e.g. ventricular emptying followed by medical carbon, it is recommended to monitor renal function, including urinary pH and acidify, if required, to prevent crystalluria. Patients should be kept well hydrated. Calcium or magnesium containing antacids may theoretically reduce the absorption of ciprofloxacin in overdoses.</p><p>Only a small quantity of ciprofloxacin (&lt;10%) is eliminated by haemodialysis or peritoneal dialysis.</p><p>In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Fluoroquinolones, ATC code: J01MA02</p><p>&nbsp;</p><p><strong>Mechanism of action</strong></p><p>As a fluoroquinolone antibacterial agent, the bactericidal action of ciprofloxacin results from the inhibition of both type II topoisomerase (DNA-gyrase) and topoisomerase IV, required for bacterial DNA replication, transcription, repair and recombination.</p><p>&nbsp;</p><p><strong>Pharmacokinetic/pharmacodynamic relationship</strong></p><p>Efficacy mainly depends on the relation between the maximum concentration in serum (C<sub>max</sub>) and the minimum inhibitory concentration (MIC) of ciprofloxacin for a bacterial pathogen and the relation between the area under the curve (AUC) and the MIC.</p><p>&nbsp;</p><p><strong>Mechanism of resistance</strong></p><p><em>In-vitro</em>&nbsp;resistance to ciprofloxacin can be acquired through a stepwise process by target site mutations in both DNA gyrase and topoisomerase IV. The degree of cross-resistance between ciprofloxacin and other fluoroquinolones that results is variable. Single mutations may not result in clinical resistance, but multiple mutations generally result in clinical resistance to many or all active substances within the class.</p><p>&nbsp;</p><p>Impermeability and/or active substance efflux pump mechanisms of resistance may have a variable effect on susceptibility to fluoroquinolones, which depends on the physiochemical properties of the various active substances within the class and the affinity of transport systems for each active substance. All&nbsp;<em>in-vitro&nbsp;</em>mechanisms of resistance are commonly observed in clinical isolates. Resistance mechanisms that inactivate other antibiotics such as permeation barriers (common in&nbsp;Pseudomonas aeruginosa) and efflux mechanisms may affect susceptibility to ciprofloxacin.</p><p>&nbsp;</p><p>Plasmid-mediated resistance encoded by qnr-genes has been reported.</p><p><u>&nbsp;</u></p><p><strong>Spectrum of antibacterial activity</strong></p><p>Breakpoints separate susceptible strains from strains with intermediate susceptibility and the latter from resistant strains:</p><p>&nbsp;</p><p><em>EUCAST Recommendations</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Microorganisms</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>S &le; 0.25 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Salmonella spp.</em></p></td><td style="vertical-align:top"><p>S &le; 0.06 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Pseudomonas&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>S &le; 0.5 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Acinetobacter&nbsp;</em>spp.</p></td><td style="vertical-align:top"><p>S &le; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus&nbsp;</em>spp.<sup>1</sup></p></td><td style="vertical-align:top"><p>S &le; 1 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 1 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>S &le; 0.06 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>S &le; 0.125 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.125 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria gonorrhoeae</em></p></td><td style="vertical-align:top"><p>S &le; 0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.06 mg/L</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria meningitidis</em></p></td><td style="vertical-align:top"><p>S &le; 0.03 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.03 mg/L</p></td></tr><tr><td style="vertical-align:top"><p>Non-species-related breakpoints<strong>*</strong></p></td><td style="vertical-align:top"><p>S &le; 0.25 mg/L</p></td><td style="vertical-align:top"><p>R &gt; 0.5 mg/L</p></td></tr><tr><td colspan="3"><p>1&nbsp;<em>Staphylococcus</em>&nbsp;spp. - breakpoints for ciprofloxacin relate to high dose therapy.</p><p>* Non-species-related breakpoints have been determined mainly on the basis of PK/PD data and are independent of MIC distributions of specific species. They are for use only for species that have not been given a species-specific breakpoint and not for those species where susceptibility testing is not recommended.</p></td></tr></tbody></table><p>&nbsp;</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>&nbsp;</p><p>Groupings of relevant species according to ciprofloxacin susceptibility (for&nbsp;<em>Streptococcus</em>&nbsp;species see section 4.4).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly Susceptible Species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Bacillus anthracis</em>&nbsp;(1)</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Aeromonas&nbsp;</em>spp.</p><p><em>Brucella&nbsp;</em>spp.</p><p><em>Citrobacter koseri</em></p><p><em>Francisella tularensis</em></p><p><em>Haemophilus ducreyi</em></p><p><em>Haemophilus influenzae*</em></p><p><em>Legionella&nbsp;</em>spp.</p><p><em>Moraxella catarrhalis*</em></p><p><em>Neisseria meningitidis</em></p><p><em>Pasteurella&nbsp;</em>spp.</p><p><em>Salmonella&nbsp;</em>spp.<em>*</em></p><p><em>Shigella&nbsp;</em>spp.<em>&nbsp;*</em></p><p><em>Vibrio&nbsp;</em>spp.</p><p><em>Yersinia pestis</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Mobiluncus</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other micro-organisms</u></p><p><em>Chlamydia trachomatis&nbsp;</em>($)</p><p><em>Chlamydia pneumoniae&nbsp;</em>($)</p><p><em>Mycoplasma hominis&nbsp;</em>($)</p><p><em>Mycoplasma pneumoniae</em>&nbsp;($)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for Which Acquired Resistance May Be a Problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecalis</em>&nbsp;($)</p><p><em>Staphylococcus&nbsp;</em>spp. *(2)</p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter baumannii<sup>+</sup></em></p><p><em>Burkholderia cepacia&nbsp;<sup>+</sup>*</em></p><p><em>Campylobacter&nbsp;</em>spp.<em><sup>+</sup>*</em></p><p><em>Citrobacter freundii*</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae *</em></p><p><em>Escherichia coli*</em></p><p><em>Klebsiella oxytoca</em></p><p><em>Klebsiella pneumoniae*</em></p><p><em>Morganella morganii*</em></p><p><em>Neisseria gonorrhoeae*</em></p><p><em>Proteus mirabilis*</em></p><p><em>Proteus vulgaris*</em></p><p><em>Providencia&nbsp;</em>spp.</p><p><em>Pseudomonas aeruginosa*</em></p><p><em>Pseudomonas fluorescens</em></p><p><em>Serratia marcescens*</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p><em>Peptostreptococcus&nbsp;</em>spp.</p><p><em>Propionibacterium acne</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently Resistant Organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Actinomyces</em></p><p><em>Enteroccus faecium</em></p><p><em>Listeria monocytogenes</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Stenotrophomonas maltophilia</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Anaerobic micro-organisms</u></p><p>Excepted as listed above</p></td></tr><tr><td style="vertical-align:top"><p><u>Other micro-organisms</u></p><p><em>Mycoplasma genitalium</em></p><p><em>Ureaplasma urealitycum</em></p></td></tr><tr><td style="vertical-align:top"><p>* Clinical efficacy has been demonstrated for susceptible isolates in approved clinical indications</p><p><sup>+&nbsp;</sup>Resistance rate &ge; 50% in one or more EU countries</p><p>($): Natural intermediate susceptibility in the absence of acquired mechanism of resistance</p><p>(1): Studies have been conducted in experimental animal infections due to inhalations of&nbsp;<em>Bacillus anthracis&nbsp;</em>spores; these studies reveal that antibiotics starting early after exposition avoid the occurrence of the disease if the treatment is made up to the decrease of the number of spores in the organism under the infective dose. The recommended use in human subjects is based primarily on&nbsp;<em>in-vitro</em>&nbsp;susceptibility and on animal experimental data together with limited human data. Two-month treatment duration in adults with oral ciprofloxacin given at the following dose, 500 mg bid, is considered as effective to prevent anthrax infection in humans. The treating physician should refer to national and /or international consensus documents regarding treatment of anthrax.<br />(2): Methicillin-resistant&nbsp;<em>S. aureus</em>&nbsp;very commonly express co-resistance to fluoroquinolones. The rate of resistance to methicillin is around 20 to 50% among all staphylococcal species and is usually higher in nosocomial isolates.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong></p><p>Following an intravenous infusion of ciprofloxacin the mean maximum serum concentrations were achieved at the end of infusion. Pharmacokinetics of ciprofloxacin were linear over the dose range up to 400 mg administered intravenously.</p><p>Comparison of the pharmacokinetic parameters for a twice a day and three times a day intravenous dose regimen indicated no evidence of drug accumulation for ciprofloxacin and its metabolites.</p><p>A 60-minute intravenous infusion of 200 mg ciprofloxacin or the oral administration of 250 mg ciprofloxacin, both given every 12 hours, produced an equivalent area under the serum concentration time curve (AUC).</p><p>A 60-minute intravenous infusion of 400 mg ciprofloxacin every 12 hours was bioequivalent to a 500 mg oral dose every 12 hours with regard to AUC.</p><p>The 400 mg intravenous dose administered over 60 minutes every 12 hours resulted in a C<sub>max</sub>&nbsp;similar to that observed with a 750 mg oral dose.</p><p>A 60-minute infusion of 400 mg ciprofloxacin every 8 hours is equivalent with respect to AUC to 750 mg oral regimen given every 12 hours.</p><p><strong>Distribution</strong></p><p>Protein binding of ciprofloxacin is low (20-30%). Ciprofloxacin is present in plasma largely in a non-ionised form and has a large steady state distribution volume of 2-3 L/kg body weight. Ciprofloxacin reaches high concentrations in a variety of tissues such as lung (epithelial fluid, alveolar macrophages, biopsy tissue), sinuses, inflamed lesions (cantharides blister fluid), and the urogenital tract (urine, prostate, endometrium) where total concentrations exceeding those of plasma concentrations are reached.</p><p><strong>Biotransformation</strong></p><p>Low concentrations of four metabolites have been reported, which were identified as: desethyleneciprofloxacin (M1), sulphociprofloxacin (M2), oxociprofloxacin (M3) and formylciprofloxacin (M4). The metabolites display&nbsp;<em>in-vitro</em>&nbsp;antimicrobial activity but to a lower degree than the parent compound.</p><p>Ciprofloxacin is known to be a moderate inhibitor of the CYP 450 1A2 iso-enzymes.</p><p><strong>Elimination</strong></p><p>Ciprofloxacin is largely excreted unchanged both renally and, to a smaller extent, faecally.</p><table border="1" cellspacing="0" cellpadding="0" style="width:632px"><tbody><tr><td colspan="3" style="vertical-align:top; width:631px"><p><strong>Excretion of ciprofloxacin (% of dose)</strong></p></td></tr><tr><td rowspan="2" style="width:257px">&nbsp;</td><td colspan="2" style="vertical-align:top; width:373px"><p><strong>Intravenous Administration</strong></p></td></tr><tr><td style="vertical-align:top; width:214px"><p><strong>Urine</strong></p></td><td style="vertical-align:top; width:159px"><p><strong>Faeces</strong></p></td></tr><tr><td style="vertical-align:top; width:257px"><p>Ciprofloxacin</p></td><td style="vertical-align:top; width:214px"><p>61.5</p></td><td style="vertical-align:top; width:159px"><p>15.2</p></td></tr><tr><td style="vertical-align:top; width:257px"><p>Metabolites (M<sub>1</sub>-M<sub>4</sub>)</p></td><td style="vertical-align:top; width:214px"><p>9.5</p></td><td style="vertical-align:top; width:159px"><p>2.6</p></td></tr></tbody></table><p>Renal clearance is between 180-300 ml/kg/h and the total body clearance is between 480-600 ml/kg/h. Ciprofloxacin undergoes both glomerular filtration and tubular secretion. Severely impaired renal function leads to increased half lives of ciprofloxacin of up to 12 h.</p><p>Non-renal clearance of ciprofloxacin is mainly due to active trans-intestinal secretion and metabolism. 1% of the dose is excreted via the biliary route. Ciprofloxacin is present in the bile in high concentrations.</p><p><strong>Paediatric patients</strong></p><p>The pharmacokinetic data in paediatric patients are limited.</p><p>In a study in children C<sub>max</sub>&nbsp;and AUC were not age-dependent (above one year of age). No notable increase in C<sub>max</sub>&nbsp;and AUC upon multiple dosing (10 mg/kg three times daily) was observed.</p><p>In 10 children with severe sepsis C<sub>max</sub>&nbsp;was 6.1 mg/L (range 4.6-8.3 mg/L) after a 1-hour intravenous infusion of 10 mg/kg in children aged less than 1 year compared to 7.2 mg/L (range 4.7-11.8 mg/L) for children between 1 and 5 years of age. The AUC values were 17.4 mg*h/L (range 11.8-32.0 mg*h/L) and 16.5 mg*h/L (range 11.0-23.8 mg*h/L) in the respective age groups.</p><p>These values are within the range reported for adults at therapeutic doses. Based on population pharmacokinetic analysis of paediatric patients with various infections, the predicted mean half-life in children is approx. 4-5 hours and the bioavailability of the oral suspension ranges from 50 to 80%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazards for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential, or toxicity to reproduction.</p><p>Like a number of other quinolones, ciprofloxacin is phototoxic in animals at clinically relevant exposure levels. Data on photomutagenicity/photocarcinogenicity show a weak photomutagenic or phototumorigenic effect of ciprofloxacin <em>in-vitro</em> and in animal experiments. This effect was comparable to that of other gyrase inhibitors.</p><p><strong>Articular tolerability</strong></p><p>As reported for other gyrase inhibitors, ciprofloxacin causes damage to the large weight-bearing joints in immature animals. The extent of the cartilage damage varies according to age, species and dose; the damage can be reduced by taking the weight off the joints. Studies with mature animals (rat, dog) revealed no evidence of cartilage lesions. In a study in young beagle dogs, ciprofloxacin caused severe articular changes at therapeutic doses after two weeks of treatment, which were still observed after 5 months.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp; Lactic acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Sodium chloride</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Hydrochloric acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Water for injection</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>Unless compatibility with other solutions/drugs has been confirmed, the infusion solution must always be administered separately. The visual signs of incompatibility are e.g. precipitation, clouding, and discoloration.</p><p>Incompatibility appears with all infusion solutions/drugs that are physically or chemically unstable at the pH of the solutions (e.g. penicillins, heparin solutions), especially in combination with solutions adjusted to an alkaline pH (pH of ciprofloxacin solutions: 3.5 &ndash; 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
Chemical and physical in-use stability has been demonstrated for 24 hours at room temperature (25°C). From a microbiological point of view, unless the method of opening and mixing with co-infusion solutions precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg; C. Avoid refrigerating or freezing.</p><p>Store in the original package in order to protect from light and evaporation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>250 ml polypropylene bags assembled with twist‐off.</p><p>Pack size: 1 Bag (200 ml).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For single use only. Discard any remaining solution after use. Keep the infusion bag within the sealed outer foil wrap before use, in order to protect it from light and evaporation. The opened pack should be used immediately.</p><p>Ciflox solution for infusion should be administered without mixing with any other substances or infusion fluids. Ciflox infusion has been shown to be compatible with ringer solution, ringer lactate solution, 5% glucose solution, 10% glucose solution and 0.9% sodium chloride solution when infused in parallel. Unless compatibility is proven, the infusion solution should always be administered separately.</p><p>When ciprofloxacin infusion solutions are mixed with compatible infusion solutions, for microbial reasons and light sensitivity these solutions must be administered shortly after admixture.</p><p>For single use only.</p><p>Do not use in case of undissolved matter is present.</p><p>The solution should be visually inspected for particulate matter and discoloration prior to administration. Only clear and colourless or slightly yellow solution should be used.</p><p>Any unused solution and the bags should be adequately disposed of, in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries
Al-Kharj Road 
P.O. Box 106229
Riyadh 11666, Saudi Arabia
Tel: + (966-11) 8107023, + (966-11) 2142472
Fax: + (966-11) 2078170
e-mail: SAPV@hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                26 October 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>